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Clinicians experienced in homeless health care routinely adapt their practice to foster better 
outcomes for their patients. This document was written for health care professionals, program 
administrators, other staff, and students serving individuals with opioid use disorders who are 
homeless or at risk of homelessness. Its purpose is to improve patient care by enhancing 
understanding of recommended strategies for the successful treatment and management of opioid 
use disorders in marginalized populations. 
  
Standard clinical guidelines often fail to take into consideration the unique challenges presented by 
homelessness that may limit access to needed services or adherence to a plan of care. To address this 
oversight, the Health Care for the Homeless (HCH) Clinicians’ Network has made the development 
of recommended clinical practice adaptations for the care of people experiencing homelessness one 
of its top priorities. Since 2002, the HCH Clinicians' Network has developed and revised nine prior 
sets of recommendations for the management of health problems that are common among homeless 
people and particularly challenging for their caregivers. These recommendations are available at: 
www.nhchc.org and www.guideline.gov. 
 
The need for adapted practice guidelines for the care of individuals with opioid use disorders and 
unstable living situations was prompted by a significant increase in deaths from opioid overdose 
reported nationwide, particularly among people experiencing homelessness. The project was 
launched at a meeting of the HCH Clinicians’ Network (CN) in October 2012, held in Nashville, 
TN. The CN Steering Committee decided to form an addiction medicine taskforce whose primary 
focus would be the development of adapted practice guidelines for homeless patients.  In 2013, an 
advisory committee comprised of 14 health and social service providers experienced in the 
management of addiction disorders for underserved populations was convened to develop clinical 
and programmatic recommendations for the care of homeless people with opioid dependence. 
These recommended practice adaptations reflect their collective judgment about optimal medical 
and non-medical interventions for this population. 
  
The recommendations in this document specify what experienced providers and recipients of 
homeless services believe works best, with the realistic understanding that limited resources, 
fragmented health care delivery systems, and loss to follow-up often compromise adherence to 
optimal clinical practices. We hope these recommendations provide helpful guidance to health care 
professionals, and that they will contribute to improvements in both quality of care and quality of 
life for people experiencing homelessness.  
 
Patricia A. Post, MPA (Editor) 
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Summary of Recommended Practice Adaptations  
For the Care of Homeless Patients with Opioid Use Disorders: 
These recommendations of the HCH Clinicians’ Network were approved by the Advisory Committee on Adapting 
Clinical Practice for Homeless Patients with Opioid Use Disorders, whose members have expertise in homeless 
health care, primary care, addiction medicine, psychiatry, harm reduction therapy, and drug overdose prevention.  
Recommended Clinical Adaptations:   
HISTORY  
 Use clinical history-taking as a critical opportunity to engage the patient and establish trust; focus on fostering 
a positive, mutually respectful relationship between the provider and patient. 
  Ask about physical and mental health and history of drug use, beginning with open-ended questions. Ask 
about personal experience as an overdose survivor and witness, including manifestations of overdose related 
trauma. 
 Ask about cultural background, living situation, history of trauma/abuse, and legal problems. 
 
PHYSICAL EXAMINATION 
 Look for physical evidence of opioid use, intoxication, or withdrawal. 
 Look for signs of skin and soft tissue infection; test for HIV/HBV/HCV infection and end-organ damage 
including liver failure. 
 Look for indications of severe depression, suicidal intent, cognitive disorders, and sequelae of trauma/abuse. 
 
DIAGNOSTIC TESTING & ASSESSMENT 
 Test patients for comorbidities that are strongly associated with opioid use disorders, including polysubstance 
use and sexually transmitted/ bloodborne infections.  
 Evaluate findings from the clinical history, physical exam, and diagnostic testing to determine diagnosis and 
severity of opioid use disorder; identify any contraindications to medication-assisted treatment or acute 
conditions requiring a higher level of care. 
 
PLAN OF CARE 
 Work collaboratively with patients to develop realistic, attainable, short-term goals for the management of opioid 
use disorders, including a personalized overdose risk reduction plan and other harm reduction strategies.   
 Determine treatment approach and setting based on patient needs and preferences, available resources, and 
affordability. Also consider motivations for seeking care, previous treatment experience, duration of disorder at 
current severity, use of heroin vs. pills, method of use, source of opioids (prescribed vs. illicitly obtained), and co-
occurring disorders.   
 Plan for close follow-up by a case manager and regular diagnostic evaluation with allowance for frequent and 
unscheduled visits. 
EDUCATION, SELF-MANAGEMENT  
 Review fundamental concepts of opioid use disorder management (treatment alternatives, side effects, risks 
and benefits); teach clients who are actively using opioids how to practice harm reduction; teach those 
currently abstaining to recognize signs and symptoms of relapse.  
 Provide opioid safety education to all patients with substance use disorders and to patients taking opioid 
analgesics on the effects of opioids, including the possibility of overdose and interactions of opioid agonists 
with other medications/ drugs of abuse.  
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 Educate patients about overdose risks, recognition and response. Offer naloxone (if possible) to any patient 
undergoing tolerance changing events such as medically supervised withdrawal procedures or medication 
assisted treatment induction.  
 Utilize tools such as motivational enhancement techniques and brief office-based counseling to help assess 
patients’ level of readiness for behavioral change. 
TREATMENT, MANAGEMENT 
 Offer medication-assisted treatment to any patient with an opioid use disorder. 
 Encourage use of nonpharmacologic interventions, whether patients are receiving medication-assisted treatment or 
not: harm reduction therapy, peer mentoring, peer support groups, acupuncture, and stable housing with access to 
supportive services including employment assistance 
 Offer needle exchange and naloxone to individuals using injected opioids, to the extent permitted by law and 
available resources. 
 Encourage more physicians serving homeless and other disadvantaged populations to seek training and 
certification to prescribe buprenorphine. 
 Encourage more primary and specialty care providers serving homeless and other disadvantaged populations to 
collaborate and integrate care with addiction treatment programs, including methadone maintenance and 
detoxification programs.  
 Develop more directly observed therapy (DOT) programs to monitor use and avoid misuse/ diversion of opioid 
agonist medications. 
ASSOCIATED PROBLEMS, COMPLICATIONS 
 Carefully assess for comorbidities that can complicate or interfere with treatment of opioid use disorders. 
Manage co-occurring conditions simultaneously. 
 Provide opioid safety education on the effects of opioids including the possibility of overdose to all patients 
with a history of substance use and to patients taking opioid medications for pain management. 
 Institute regular monitoring of all medications prescribed for and taken by the patient to prevent prescription 
of lethal or nontherapeutic medication combinations and to reduce risk of prescribing medications that will 
trigger relapse in patients with substance use disorders. 
 If diversion/misuse of opioid agonists is suspected, explore patient motivations; re-evaluate the plan of care; 
implement strategies to minimize risk of diversion/ misuse (random drug tests, alternate day dosing, 
prescription monitoring program, directly observed therapy). Balance overall benefits of continuing MAT 
with potential harms. 
FOLLOW-UP 
 Determine frequency of follow-up based on stability of the patient and his/her living situation and risk of 
diversion/ misuse/ abuse of medications used for treatment of opioid use disorders or other substances. 
 At each visit, assess for behaviors outside the treatment plan, including a psychosocial assessment. Consider 
causes related to homelessness — missed appointments due to competing priorities or unexpected events (e.g., 
in jail, delayed by another appointment), stolen medications (e.g., assault, theft in shelter).  
 Provide medical respite care facilities where patients can convalesce when ill, recuperate following 
hospitalization, or receive end of life care. Facilitate entry into permanent housing with supportive services on 
site or in the community, to alleviate many associated problems and complications. 
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Recommended Programmatic Adaptations: 
 
SERVICE DELIVERY DESIGN 
 Design service delivery systems based on meeting patient needs, promoting consistency in practice, and 
supporting staff that work with challenging patients.   
 Consider use of unconventional treatment sites (e.g., mobile methadone vans), addiction counseling on a 
drop-in basis, flexible treatment goals and desired outcomes, and creative strategies for recruiting patients 
into treatment. 
 Establish collaborative relationships with methadone maintenance providers, detoxification programs, and 
other inpatient and outpatient addiction treatment programs for cross referral and coordinated care. 
 Integrate primary and behavioral health care and use a harm reduction approach to the management of 
opioid use disorders. Use multidisciplinary clinical teams working at the same location. Locate treatment 
activities in places where homeless individuals with substance use disorders congregate. Provide recovery-
oriented support services (e.g., peer mentoring, group therapy, employment assistance). 
OUTREACH AND ENGAGEMENT 
 Use outreach workers in the community to facilitate initial engagement with and provide support to people 
at risk for opioid overdose. Do outreach in partnership with a consumer/peer counselor as much as possible.  
 Provide ongoing opportunities for group therapy to patients with opioid use disorders. 
 If possible, provide medication-assisted treatment where homeless people live (e.g., shelter-based treatment 
with buprenorphine). 
 Use a team approach in care planning and coordination to facilitate engagement. 
 
STANDARDS OF CARE 
 Adapt clinical practices to optimize care for patients who are homeless or at risk of becoming homeless 
considering the recommendations contained in this guide.  
 Offer medication-assisted treatment to any patient with an opioid use disorder.  
 Address acute and chronic medical problems related to drug use. 
 Offer naloxone to patients with an opioid use disorder and offer needle exchange to injecting drug users, to 
the extent permitted by law and available resources. 
 Advocate for improved access for homeless and other underserved populations to a broader range of 
interventions for the management of opioid use disorders. 
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INTRODUCTION   
 
Opioids are opium derivatives and related synthetic substances that suppress pain, produce euphoria, 
and are employed to treat neurological and behavioral disorders resulting from opioid misuse. 
Although they are invaluable therapeutic agents, these powerful drugs are also addictive; and 
medication errors, misuse, overdose, and poisonings cause numerous fatalities annually. Illicit use of 
opioids – both heroin and prescribed analgesics such as oxycodone, hydrocodone, and fentanyl – has 
reached epidemic proportions in the United States (Preda & Dunayevich 2013, SAMHSA 2012 Sep, 
Alford 2007). In 2008, over 36,000 people died in the U.S. as a result of drug overdose. The majority of 
these deaths involved prescription opioid analgesics (CDC 2011). Opioid use disorders1 occur along a 
continuum of severity, with different patterns of use in urban and rural areas and within different 
subpopulations – e.g., more heroin use in urban areas, involving older, more ethnically diverse users; 
more non-heroin opioid use in rural areas by younger, non-Hispanic Whites (SAMHSA 2012 Jul).  
Opioid use is frequently a component of polysubstance use disorders. 
Opioid poisonings and overdose deaths occur throughout all segments of society, but clinicians serving 
people who are homeless2 or unstably housed report that these individuals are at especially high risk for 
both opioid use disorders and fatal overdoses, exacerbated by their limited access to medication-assisted 
treatment and to overdose prevention therapy (HCH Clinicians’ Network 2006 Oct & 2009 Feb). A 
five-year study of 28,033 homeless people who had received treatment from the Boston Health Care for 
the Homeless Program between 2003 and 2008 found that drug overdose had replaced HIV as the 
leading cause of death among homeless adults in Boston and was responsible for one-third of fatalities 
of those between the ages of 25 and 44. Opioid analgesics and heroin were implicated in 81% of 
overdose deaths. Homeless adults aged 25–44 were nine times more likely to die than comparably aged 
housed adults in Massachusetts, and those aged 45–64 were 4.5 times more likely to die. (Baggett 2013).  
                                                 
1
  Opioid use disorder: “A problematic pattern of opioid use leading to clinically significant impairment or distress,” as 
manifested by at least two of 11 diagnostic criteria specified in the American Psychiatric Association's Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), 2013. Severity of the DSM-5 substance use disorders is based 
on the number of criteria endorsed: 2–3 criteria indicate a mild disorder; 4–5 criteria, a moderate disorder; and 6 or 
more, a severe disorder.  
2
 A homeless person, as defined by the Bureau of Primary Health Care, is “… an individual without permanent housing 
who may live on the streets; stay in a shelter, mission, single room occupancy facility, abandoned building or vehicle; or in 
any other unstable or non-permanent situation. An individual may be considered to be homeless if that person is ‘doubled 
up,’ a term that refers to a situation where individuals are unable to maintain their housing situation and are forced to 
stay with a series of friends and/or extended family members. In addition, previously homeless individuals who are to be 
released from a prison or a hospital may be considered homeless if they do not have a stable housing situation to which 
they can return. A recognition of the instability of an individual's living arrangement is critical to the definition of 
homelessness.” [emphasis added] (Principles of Practice: A Clinical Resource Guide for Health Care for the Homeless Programs, 
Bureau of Primary Health Care/HRSA/HHS, 3/1/99; PAL 99–12.)  [The authors of these adapted practice guidelines 
understand that ‘experiencing homelessness’ is a more respectful and accurate way of designating individuals with unstable 
living situations than labeling them as ‘homeless.’ The latter expression is occasionally used in this document for the sake of 
brevity, but should be understood to connote a variable condition rather than a permanent characteristic.]  
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Numerous factors associated with homelessness may increase the risk of developing severe opioid use 
disorders and make treatment more difficult – including complex and poorly treated comorbidities, 
insufficient resources to meet basic needs, minimal social supports, and lack of access to specialty care. 
People experiencing homelessness are less likely to have clean, safe and comfortable locations to use 
opioids, which results in rushed and riskier drug use behaviors. Other realities of homelessness that 
may precipitate or exacerbate these disorders are high vulnerability to physical/ sexual abuse and living 
with unrecognized or untreated behavioral health problems, including psychological sequelae of trauma 
or abuse and cognitive impairment. These factors also make adherence to medical and mental health 
treatment plans and personal risk reduction plans more difficult. Chronic health conditions often 
associated with opioid use disorders that require regular, uninterrupted treatment – such as HIV 
infection and mental illness – are difficult to manage in unstable living situations. “The relationship 
between chemical dependence and homelessness is interactive; one condition does not necessarily cause the other, 
but each can exacerbate problems associated with the other. Substance abuse can be both a precipitating factor and 
a consequence of homelessness.” (Zerger 2002) 
Barriers to treatment for homeless people with opioid use disorders 
Limited access to addiction treatment and fragmented health care delivery systems present significant 
obstacles to medical care for homeless people with substance use disorders, many of whom have serious 
co-occurring disorders (Ibid.). Lack of safe and affordable housing, instability, and social isolation 
complicate treatment. Lack of health coverage and other financial resources may make medication-
assisted treatment unaffordable. Limited family and peer support for maintaining sobriety present 
barriers to recovery. Homeless people with uncontrolled opioid use disorders are at high risk for 
incarceration. Access to medication-assisted treatment during and after incarceration is limited; only 
55% of prisons in the United States provide methadone to inmates and only 14% provide 
buprenorphine. Many correctional facilities oppose pharmaceutical treatment of opiate dependence as 
a matter of policy, preferring abstinence-only programs for incarcerated individuals; and following 
release, most prisons do not offer referrals to treatment programs. (Nunn 2010) A criminal history 
related to drug use may create additional barriers to housing, employment, and public assistance 
benefits. Discrimination based on race, gender, sexual orientation, or chemical dependence exacerbates 
financial and structural barriers to care. 
 
Opioid-dependent, homeless people are frequently denied care by the medical community because they 
are stereotyped as “drug seeking” or “difficult.” Barriers to effective treatment and management of 
opioid use disorders also include poor understanding of addiction treatment and recovery by medical 
practitioners, the unwarranted assumption that substance abuse treatment for homeless people is 
unsuccessful, reluctance of physicians to use opioid agonist treatment despite its demonstrated efficacy, 
lack of authorization for nurse practitioners and physician assistants to prescribe opioid agonist 
medications, and exclusionary clinical guidelines requiring housing stability as a prerequisite for 
treatment with opioid agonists (Alford 2007, Hersh 2011, Zevin 2011, Stancliff 2012). 
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Successful interventions & promising practices 
Despite these impediments, both research and clinical experience suggest that health outcomes and 
quality of life can be significantly improved with a comprehensive, client-centered approach to the 
management of opioid use disorders and comorbid conditions. Practitioners with expertise in homeless 
health care, primary care, addiction medicine, psychiatry, harm reduction, and overdose prevention 
recommend the following interventions to promote successful treatment of homeless patients with opioid 
use disorders: a harm reduction/ low-threshold model of care (Denning & Little 2011, Zevin 2011, 
Stancliff 2012); explicit overdose prevention and management training and naloxone rescue kit access 
(Wheeler 2012, Walley 2013); integration of primary care with mental health and addiction services 
provided by a multidisciplinary clinical team (Meinbresse 2013, Goyer 2011); use of creative outreach 
strategies and unconventional treatment sites with flexible service access (Bonin 2010); intensive case 
management and peer support to improve treatment adherence and promote recovery (Alford 2007, 
Herinckx 2008); flexible, individualized treatment goals established in collaboration with patients 
(Wismer 2011); and provision of/ referral to transitional or permanent housing with supportive services 
including employment assistance (Perlman & Parvensky 2006, Herinckx 2010, HCH Clinicians’ 
Network 2006 Oct, 2009 Feb). 
Several studies have demonstrated the feasibility of office-based opioid treatment (OBOT) for homeless 
patients using sublingual buprenorphine. Study results published in 2007 by researchers in Boston 
demonstrated that opioid-dependent homeless and housed cohorts receiving OBOT with 
buprenorphine/naloxone had comparable outcomes (did not differ in risk for treatment failure during 
follow-up and had similar proportions of treatment successes), despite the homeless cohort's greater social 
instability, medical and psychiatric comorbidities, and chronic drug use (Alford 2007). In 2011, The San 
Francisco Department of Public Health reported results from a two-year OBOT-buprenorphine/naloxone 
pilot program in which over 80% of patients were injecting heroin at baseline, 40% of whom were 
homeless. Positive outcomes included a one-year retention rate of 61% and a rapid and dramatic decline 
in opioid use (Hersh 2011). A 32-month pilot study in New York City demonstrated that 
buprenorphine/naloxone could be successfully used to treat homeless heroin users using a harm 
reduction model of care (Stancliff 2012).  
Studies involving homeless recipients of methadone maintenance treatment (MMT) have focused on 
treatment retention rates for heroin-dependent injection drug users (IDUs) at high risk for HIV infection, 
client factors involved in MMT retention, and the association between longer MMT retention and 
improved outcomes for individuals with co-occurring opioid dependence and HIV infection. A study of 
street-recruited IDUs in Denver, Colorado, 1996–2000, found that 60% of those who entered MMT 
remained for at least 90 days, indicating the viability of methadone maintenance even for more 
marginalized drug users (Booth 2004). This study also supports the efforts of outreach interventions in 
facilitating treatment entry and retention for homeless heroin users who may not have been 
contemplating treatment at the time they were contacted.  A study of adult IDUs entering a licensed 
MMT program in Massachusetts,1996–2002, found that homeless patients were 15% less likely than 
housed patients to remain in MMT for 1 year or more (Lundgren 2007). Subjects who were younger, 
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male, homeless, uninsured, and had previously used residential treatment were significantly more likely to 
have remained in MMT for 6 months or less compared with their counterparts.  A prospective study of 
HIV-infected IDUs in Vancouver, Canada, 1996–2008, found that MMT was positively associated with 
adherence to antiretroviral therapy (ART), whereas homelessness and frequent heroin use were negatively 
associated with ART adherence (Palepu 2011). Homeless subjects were slightly younger and more likely to 
inject heroin daily than their non-homeless counterparts. 
Research on the clinical effectiveness of naltrexone for the treatment of opioid dependence in 
homeless/marginal populations is scarce. In general, the clinical utility of oral naltrexone has been 
limited by poor treatment adherence and retention; the majority of patients who are prescribed this 
medication do not adhere and drop out rapidly (ASAM 2013). Behavioral interventions such as 
contingency management with vouchers and involvement of significant others in treatment monitoring 
have been shown to improve naltrexone adherence, increase treatment retention, and reduce opioid use 
(Carroll 2001). Recent studies of opiate-addicted, unemployed adults have found poor to modest 
treatment adherence using extended-release injectable naltrexone (XR-NTX) without incentives; 
adherence rates are substantially higher when employment-based reinforcement incentives are made 
contingent on treatment (Everly 2011, DeFulio 2012).  
Purpose of this document and intended audience 
The purpose of this document is to educate clinicians, other direct service providers, and program 
administrators about optimal care for people with opioid use disorders who are homeless or marginally 
housed, addressing clinical and programmatic issues.  The development of these adapted practice 
guidelines was precipitated by 1) a significant increase in deaths from opioid overdose reported 
nationwide, particularly among people experiencing homelessness (NIDA 2013, Malone 2013, Baggett 
2013, Preda & Dunayevich 2013); 2) the awareness that opioid use disorders remain a pervasive public 
health problem contributing to the spread of infectious diseases and crime (Alford 2007, Herinckx 
2008, Stancliff 2012); and 3) a recognition of the need for evidence-based practice guidelines for the 
care of underserved populations with opioid use disorders. 
 
The same standards of care are warranted for people experiencing homelessness as for people with 
stable housing. Nevertheless, primary care providers who routinely serve homeless individuals recognize 
an increased need to take living situations and co-occurring disorders into consideration to develop a 
feasible plan of care. The practice adaptations recommended in this document are based on a 
comprehensive review of published reports and the consensus opinion of experienced homeless services 
providers and recipients with expertise in primary care, addiction medicine, psychiatry, harm reduction 
therapy, and overdose prevention. These recommendations are intended to be consistent with the 
clinical practice guidelines listed below. Their purpose is to facilitate adherence to these standards in 
the care of impoverished, displaced persons with multiple medical and psychosocial problems, many of 
whom lack safe and stable housing, affordable and accessible health care, and financial and social 
resources to meet basic needs, including nutritious food, clothing, shelter, and transportation.  
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Primary Sources 
Primary sources for these recommendations are the Substance Abuse and Mental Health Services 
Administration’s TIP 55: Behavioral Health Services for People Who Are Homeless (2013); the Department of 
Veteran Affairs’ Clinical Practice Guidelines for the Management of Substance Use Disorders (2009); the clinical 
practice guideline on Buprenorphine/Naloxone for Opioid Dependence (2011) by Handford and colleagues at the 
Centre for Addiction and Mental Health, Toronto, Ontario; and Adapting your Practice: Recommendations for the Care 
of Homeless Adults with Chronic Non-Malignant Pain (2011) developed by Wismer et al. for the Health Care for the 
Homeless Clinicians’ Network, National Health Care for the Homeless Council, with support from the Health 
Resources and Services Administration (see page 68 for full citations).  In general, treatment 
recommendations found in these sources are not restated in this document except to clarify a particular 
practice adaptation or to emphasize standard practices that are not well understood by clinicians 
serving homeless patients with opioid use disorders.   
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Recommendations for the Care of  
Homeless Patients with Opioid Use Disorders 
 





 Initial history  Recognize that many people with a history of homelessness have negative 
associations with medical settings. Clinical history-taking is an important opportunity to foster a 
positive, mutually respectful relationship between the provider and patient that should be 
reinforced at every subsequent encounter. Allow patients to tell their story and listen 
nonjudgmentally. Build confidence that as their provider, you have their best interest at heart. 
Briefly explain your clinical background and what your facility might have to offer them. (Health 
care settings serving homeless people range from triage sites to comprehensive primary care clinics.) 
Explain at the outset that you are going to ask about their physical health, mental health, and use of 
prescribed and nonprescribed drugs. Many of these questions can be asked over time and are 
helpful in building rapport, developing an appropriate treatment plan, and fostering a successful 
collaborative relationship. 
 Medical history  Ask patients to describe their physical health and listen for several minutes 
without interrupting. Use reflection — a kind of supportive interruption — to show them that you 
heard exactly what they said. Then ask specifically about individual and family history of conditions 
associated with opioid use disorders, including traumas, personal losses, and chronic pain. Due to 
recent concerns regarding EKG QTc intervals and methadone treatment, primary care providers of 
Major recommendations: 
 Use clinical history-taking as a critical opportunity to engage the patient and establish trust; focus 
on fostering a positive, mutually respectful relationship between the provider and patient. 
 Ask about physical and mental health and history of drug use, beginning with open-ended questions. 
Ask about personal experience as an overdose survivor and witness, including manifestations of 
overdose related trauma. 
 Ask about cultural background, living situation, history of trauma/abuse, and legal problems. 
Rationale: Many people experiencing homelessness have had negative experiences with the health care system, so 
developing a therapeutic relationship is a key objective in addition to getting an accurate history. Both are important 
for developing a successful plan to address opioid use disorders. 
Evidence: Expert consensus. Although there is limited scientific evidence to support these recommendations, many 
clinicians with expertise in homeless health care, primary care, addiction medicine, psychiatry, and harm reduction 
therapy find this approach to history-taking helpful.  
Sources: Alford 2007, Bonin 2010, Greenberg & Rosenheck 2008, Highley 2008, Hwang 2008, Khoury 2010, Kushel 
2003, SAMHSA 2013,Wismer 2011 
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patients known to have opioid use disorders should obtain thorough cardiac histories, including 
history of syncope, congestive heart failure, arrythmias, and cardiac surgery (Martin 2011). This 
information is useful for safe patient management if referred to a methadone treatment program.  
Ask whether patients have ever been hospitalized, and if so, where and for what reason(s). Inquire 
about other health care providers and whether there is a regular source of primary care. Ask about 
all current and past medications and dietary supplements taken, including contraceptives, over-the-
counter medicines, herbal remedies, dietary supplements, and any “borrowed” medicine prescribed 
for others. Ask about any problems adhering to prescribed treatment and any adverse or strange 
side effects noticed. Assess ability to take pills daily and return for follow-up care; ask about regular 
routines and prior experience with medical treatment. 
 Psychiatric history  Ask patients to tell you about their mental health and any “problems with stress, 
low energy, difficulty focusing, or mood swings.” Ask if they have ever seen a psychiatrist or therapist 
and if so, whether they were given a diagnosis. Ask if they have ever been treated for depression, 
anxiety, or other mental health concerns and if they are currently experiencing any of these problems.  
PTSD, depression, and anxiety are strongly associated with opioid use disorders, and may be 
exacerbated by personal or witnessed overdose experience. Ask patients if they are bothered by 
“thoughts or sensations that seem unusual or supernatural  (hallucinations)” and if they have ever 
considered suicide. Recognize that psychiatric illness can complicate treatment of opioid use disorders 
and other comorbidities.  
 History of drug use  or every new patient, begin the interview with questions about cigarette use, 
which are expected in a medical setting and nonthreatening. Then follow up with questions about 
personal and family history of alcohol use and drug use, including nontherapeutic use of prescribed 
medications. Follow-up questions can be standardized questions suggested by the National Institute 
on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse, or questions like: 
“Have alcohol or drugs been a problem? Have you needed treatment for alcohol or drug problems?” Patients 
are open to answering these questions when asked in this nonjudgmental way. Begin with open-
ended questions; resist the urge to interject questions that are too specific with an agenda. Ask 
about current and past drug use in different ways, depending on the setting and what you have 
already learned about the patient. Remember that patients may not give a full history at the first 
encounter. Later disclosure should not lead to a conclusion that patients are not concerned about 
their health.   
If personal drug use is acknowledged, inquire about both perceived benefits associated with drug 
use and any drug-related problems the patient has experienced (e.g., blackouts/seizures, suicidal 
thoughts/actions, endocarditis, other infections requiring treatment/ hospitalization, withdrawal 
symptoms, previous nonfatal overdose, legal issues related to drug/alcohol use). Document any 
previous treatment for substance use disorders and attempts at recovery. Ask specifically about 
participation in a methadone or buprenorphine program, attempts to moderate substance use, 
previous experience with 12-Step groups, and other self-help and peer group strategies. Ask patients 
Health Care for the Homeless Clinicians’ Network 
ADAPTING YOUR PRACTICE 
Recommendations for the Care of Homeless Patients with Opioid Use Disorders  
11 
whether they have ever overdosed, witnessed an overdose, or received training to prevent, 
recognize, or respond to a drug overdose. 
SUGGESTED QUESTIONS TO ELICIT INFORMATION ABOUT DRUG USE 
 Are you seeking care for a drug problem? If so, explore the patient's motivations for seeking care. Were you 
required by the legal system or family/peer pressure to seek care? Patients may be highly motivated to obtain care 
whether they are seeking treatment voluntarily or because they feel pressured to do so. Careful, nonjudgmental 
eliciting of patient goals is essential. Atypical/ unconventional motivations may be acceptable but require careful 
evaluation and follow-up.  
 Have you ever received treatment for your drug problem before?  If so: What worked well, what did not, and 
why do you think relapse occurred? What do you think might be helpful this time, and how might you do things differently? 
What coping skills have you developed in dealing with homelessness/ unstable housing that might be utilized during this 
attempt at recovery/treatment? If not: Ask if the patient has ever self-treated a drug problem before, including home 
detox, tapering, or experience with illicitly acquired buprenorphine or methadone. 
 What happens when you stop taking the drug or can’t obtain the usual drug or amount?  Have you ever had 
a stroke or seizure after you stopped taking a drug? Explore type of withdrawal symptoms and time until withdrawal 
symptoms occurred.  
 Describe in detail any period of time when you were able to maintain sobriety. Were you housed? If so: What 
type of housing? What types of support were you utilizing (e.g., Alcoholics Anonymous, Narcotics Anonymous, counseling, 
church, yoga, other exercise)? What happened or what did you stop doing before you began using again? 
 Have you or has anyone in your family ever used pills or drugs prescribed for pain? If so: What pills/drugs 
were used and how (swallowed, injected, sniffed, smoked)? How much of the drug(s) was used and when? If considering 
medication-assisted treatment for patients using opioids, ask: When was the last time you used? How much did you 
use? What are you feeling now? How long is the current “run” since the last treatment or sobriety?  
 Have you or a family member ever had any odd experiences after taking a prescribed or nonprescribed 
drug?  If so: Who had such experiences, using what drug(s)? Please describe the odd experience. This question is 
designed to assess the possibility of drug-induced psychosis (delusions, hallucinations). Ask patients known to have 
a psychotic disorder seeking treatment for opioid dependence whether their psychosis has gotten worse after 
they stopped using opioids; there is some evidence that opioids have anti-psychotic effects. Individuals who answer 
yes may need closer psychiatric follow-up.   
 What are positive and negative effects of drug use?  Compare patient- versus provider-identified benefits and 
adverse consequences of using. Have you or has anyone in your family attempted suicide after taking a prescribed or 
nonprescribed drug and/or alcohol?  If so: What drug(s)/ alcoholic drink(s) were used? Please describe what happened. Ask 
specifically about drug overdose: Have you ever overdosed? Witnessed a drug overdose? Were any fatal? If so, offer 
overdose prevention and response materials including naloxone and assess for trauma/PTSD. If not, discuss 
personal strengths and planned drug use decisions: What strategies do you use to protect yourself from overdose? 
Patients who have used or are using illicit drugs need reassurance that the information they provide to you will 
not be accessible to police or the criminal justice system, within specified limits of confidentiality. 
 Is a health care provider coordinating all of your prescribed medications?  If yes, ask for the provider's name, 
phone number, and area of clinical expertise, if known—e.g., primary care provider? specialist in treating substance use 
disorders? Patients may not be willing to disclose this information about a provider who is supplying medications 
that they are abusing. It is important to gain the patient's trust regarding the importance of sharing this 
information in order to best serve their needs.  
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Screening tools such as CAGE, AUDIT-C, DAST and substance dependence check lists can help 
determine where a patient is within the spectrum of substance use disorders. A validated scale for 
assessing withdrawal is the Clinical Opiate Withdrawal Scale (COWS). In homeless health care 
settings that serve patients with a high prevalence of substance use disorders, the majority of patients 
“screen in.” The added value of substance use screens is questionable with high prevalence 
populations when direct questioning and observation confirm the presence of these disorders. In 
lower prevalence settings or with patients who have not disclosed a substance use problem, validated 
screening tools may be more useful. (Wismer 2011)  Screening instruments can stimulate a fruitful 
discussion of substance use between patient and provider. 
 Legal problems  Many homeless people come to clinics seeking legally-mandated treatment for 
opioid use disorders, but providers may have difficulty meeting the court's requirements for truly 
random urine tests with an intact chain of custody, mandatory group attendance, and reports to 
probation or parole officers. Asking about legal issues related to substance use can be helpful in 
identifying patients at increased risk for chronic substance dependence. Ask about the patient’s 
current/past legal problems and if there is a history of incarceration. If so, ask whether the person 
ever received medical, mental health, or substance abuse treatment while incarcerated. Ask whether 
legal problems created difficulty accessing treatment because the offense involved physical or sexual 
violence. Ask about custody of children and any problems with Child Protective Services. Request 
information about any probation or parole requirements. Behavioral health disorders are major 
contributors to the high rate of homelessness among incarcerated people; and a history of 
incarceration is associated with interrupted treatment, increased risk of infectious diseases, and 
barriers to employment and housing following discharge (Greenberg & Rosenheck 2008).  
 Trauma/ abuse Be aware of the association between trauma and substance use disorders (Khoury 
2010). A high percentage of homeless people have experienced physical, sexual, and/or emotional 
abuse as children and as adults; many have been mistreated for their sexual orientation and/or 
gender identity. Homeless women and transgender persons are among those at highest risk for sexual 
and physical assault (Kushel 2003). Elicit information about a history of trauma/ abuse: Has anyone 
ever hurt you? Are you safe now? Have you had to have sex in exchange for drugs? Inquire about head 
injuries, falls, assaults, accidents, participation in military combat or contact sports, and if the 
patient has ever been knocked unconscious or been in a coma. Did you ever hit your head or pass out? 
Do you have bad dreams? If so, inquire about symptoms associated with traumatic brain injury  (TBI): 
difficulty concentrating, headaches, seizures, short and long-term memory loss, excessive emotional 
reactions/ frequent mood changes and irritability, dizziness, fatigue, insomnia, impulsivity, 
distractibility, and poor organizational/ decision making skills. Significant numbers of people 
experiencing homelessness report histories of blows to the head, often related to severe physical 
abuse sustained in childhood, motor vehicle accidents, falls, or military combat (Highley 2008; 
Hwang 2008). This information can be helpful in identifying patients at higher risk of opioid 
misuse (e.g., trauma survivors and those with chronic pain), as well as patients who may have 
trouble adhering to the treatment plan (impulsivity), and may suggest the need for a more 
structured treatment plan. 
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 Living situation & social support  Ask patients about their living situation to determine residential 
stability and identify environmental factors that may threaten health and safety. (Where are you 
currently staying? Is the place where you live adequate? overcrowded? safe? Do you live there with other people?) 
Ask where they sleep and spend time during the day and how they can be contacted. Ask explicitly 
about access to food, water, shelter, restrooms, and a place to store medications. (Bonin 2010)  If 
patients are known to be homeless, try to understand the circumstances that precipitated 
homelessness. Inquire about cultural background, faith community/other affiliations, and current 
relationships to assess family/community supports. Recognize that an unstable living situation and 
lack of social support and are among the factors that can increase risk of treatment failure/relapse 
for patients with opioid use disorders, and that more clinical support and case management are 
required to mitigate these risks (Alford 2007). 
 Perceived aspirations, strengths & challenges  Ask patients about their aspirations, personal 
strengths, and goals to promote self-esteem, celebrate resilience, and encourage realistic self-
assessment, all of which are important for behavioral change. Recognize that a large percentage of 
homeless drug users have histories of childhood trauma and are preoccupied with meeting basic 
daily needs. In asking about goals or aspirations, it may be helpful to focus more on the present and 
near future than the past. 
What do you wish were different in your life?   
What are your strengths—things you are good at? 
What has given you the strength to survive despite homelessness? 
What barriers or issues are preventing you from making your wishes come true? 
How do you learn best and remember things?  
What are your goals or plans for the next 1–6 months?  
What is your one-year plan? What are your plans for the next two years or longer?  
 Review of systems  Ask patients about specific symptoms related to opioid use that are not elicited 
by the clinical history – issues regarding skin lesions, pain, current problems with memory/ mood/ 
anxiety, current symptoms of withdrawal or intoxication.  If looking for symptoms of opioid 




 “We are not treating an illness or a lab value, but a person. Understanding that person within the 
context of his or her life is critical to everything we do as clinicians. Fractured lives, lack of support 
from family or other relationships which have often been damaged by drug-seeking behavior, lack of 
vocational and social context – these are among the factors that make the situation of homelessness 
relevant to the care of individuals with opioid use disorders. Every individual has a story, and the more 
we know about our patients’ stories and situations, the more appropriately we can treat them.”  
           — Ansell Horn, FNP, Lutheran Healthcare, Brooklyn, New York 
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 Look for physical evidence of opioid usage, intoxication, or withdrawal. 
 Look for signs of skin and soft tissue infection; test for HIV/HBV/HCV infection and end-organ damage 
including liver failure. 
 Look for indications of severe depression, suicidal intent, cognitive disorders, and sequelae of trauma/ 
abuse. 
Rationale: Because a history of substance use related problems may not be initially revealed, it is important to look for 
physical signs of drug use, including use of prescribed medications, alcohol, and nicotine. Injection of heroin is a common 
vehicle of HIV and hepatitis B/ C infection. Uncontrolled mental health disorders can complicate medication-assisted 
therapy and should be treated simultaneously. All of these conditions are among comorbidities commonly seen in 
homeless patients with opioid use disorders. 
Evidence: Recommendations are based on expert consensus of practitioners experienced in homeless health care with 
expertise in primary care, addiction medicine, and psychiatry.  Sources: SAMHSA 2013, Preda 2013, Bonin 2010 
 
 
 Physical evidence of opioid usage/ intoxication/ withdrawal  Look for signs of injecting 
(trackmarks over veins, abscesses and other soft tissue infections, old scars); signs of intranasal drug 
use (snorting) such as swollen nasal mucosa or a deviated septum; and for current signs/ symptoms 
of intoxication (somnolence, small pupils) and withdrawal  (yawning, dilated pupils, piloerection, 
tachycardia and  hypertension, lacrimation hyperthermia).  
 Medical examination  Perform a comprehensive medical examination, including analysis of 
laboratory test results. Look for: 
- Skin and soft tissue infection 
- Signs of HIV infection  
- Presence of hepatitis B or C  
- Signs of end-organ damage including liver failure (low platelet count, low albumen, physical 
signs of cirrhosis) 
Remember that conditions related to cigarette smoking are among the most common causes of 
morbidity and mortality in substance users. 
 Mental status examination  Look for:  
– Indications of severe depression, including suicidal intent 
– Difficulty understand directions 
– Ability to follow 2 and 3 step directions 
– Thought content that is predominantly bizarre or paranoid 
– Thought processes that are difficult to follow 
 Physical evidence of trauma/ physical abuse  Look for acute or sub-chronic injuries like bruising 
and healing fractures to assess current safety. 
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 DIAGNOSTIC TESTING & ASSESSMENT  
 
  Major Recommendations: 
 Test patients for comorbidities that are strongly associated with opioid use disorders, including 
polysubstance use and sexually transmitted/ bloodborne infections.  
 Evaluate findings from the clinical history, physical exam, and diagnostic testing to determine 
diagnosis and severity of opioid use disorder; identify any contraindications to medication-assisted 
treatment or acute conditions requiring a higher level of care. 
Rationale: Many homeless patients have comorbidities that complicate the management of opioid use disorders; they 
should be assessed during the clinical history for health conditions that may complicate treatment for opioid use disorders. 
Laboratory tests are important to facilitate diagnosis and guide treatment planning. 
Evidence: Expert consensus of practitioners in homeless health care with expertise in primary care, addiction  
medicine, and psychiatry.  Sources: Wismer 2011, HCH Clinicians' Network 2014  
 
Diagnostic Testing 
Test patients for comorbidities strongly associated with opioid use disorders, including polysubstance 
use, chronic infections transmitted by injection drug use/sexual contact/congregate living in shelters or 
jails; and other conditions that may complicate treatment. Use urine toxicology/ blood serology to 
detect the presence of opioids in patients suspected of opioid use disorders, and to monitor patients on 
prescription opioids. Testing should be targeted at specific goals. 
 Baseline laboratory evaluation:  complete blood count (CBC), complete metabolic panel (CMP), 
liver function tests, lipid profile, urine toxicology (with patient's permission). Consider serum 
toxicology as an adjunct or if urine is unobtainable.  
 Infectious disease evaluation:  
Sexually transmitted/bloodborne infections: gonorrhea, chlamydia, syphilis (RPR), 
trichomoniasis, bacterial vaginosis, monilia (Candida Albicans), HIV infection (HIV antibody),  
hepatitis B (HBV antibody and antigen) and C (HCV antibody) 
Tuberculosis: The CDC recommends tuberculin skin testing (TST/PPD) or TB blood testing 
(QFT/ T-Spot) for people living or working in locations where TB disease is more common, 
including homeless shelters, prison or jails; and for people who use illegal drugs. TB testing is 
recommended every six months for homeless patients because of their higher risk for contact with 
active tuberculosis and unpredictable follow-up. Various agencies, including homeless shelters, 
require proof of TB testing. (HCH Clinicians’ Network 2014) 
 Pregnancy test: Use human chorionic gonadotropin (hCG) urine test for pregnancy in women of 
child bearing potential. Recognize that opioid-dependent women who are homeless typically have 
high-risk pregnancies due to inadequate nutrition and rest, limited prenatal care, maternal and fetal 
exposure to fluctuating levels of drugs in the mother's bloodstream, as well as exposure to HIV, 
HCV, and other bloodborne pathogens associated with injection drug use (ASAM 2013). 
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Assessment   
Diagnosing Opioid Use Disorders 
 Essentials for initial evaluation  Use information from the history and initial physical examination 
for diagnosis of opioid use disorder. Determine level of severity to identify patients with mild enough 
syndrome who might respond to detox and/or non-medication-assisted outpatient treatment, and to 
identify patients with contraindications to buprenorphine treatment or acute conditions requiring a 
higher level of care (e.g., hospitalization for severe alcohol/ heroin addiction).  
 Diagnostic criteria  In the American Psychiatric Association’s Diagnostic and Statistical Manual, 
Fifth Edition (DSM–5), published in May 2013, the DSM-IV criteria for substance abuse and 
substance dependence have been combined into single substance use disorders specific to each 
substance of abuse within a new ‘Addictions and Related Disorders’ category. Legal problems have 
been dropped, and craving is added as a criterion. Each substance use disorder is divided into mild, 
moderate, and severe subtypes. Severity is based on the number of criteria satisfied: 2–3 criteria 
indicates a mild disorder; 4–5 criteria, a moderate disorder; 6 or more criteria, a severe disorder.  
 
DSM-5 Diagnostic Criteria for Opioid Use Disorder:  
A problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by at least 
two of the following, occurring within a 12-month period: 
1. Opioids are often taken in larger amounts or over a longer period than was intended.  
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use. 
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its effects.  
4. Craving, or a strong desire or urge to use opioids. 
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, or home. 
6. Continued opioid use despite having persistent or recurrent social or interpersonal problems caused or 
exacerbated by the effects of opioids.  
7. Important social, occupational, or recreational activities are given up or reduced because of opioid use 
8. Recurrent opioid use in situations in which it is physically hazardous. 
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem 
that is likely to have been caused or exacerbated by the substance.  
10. Tolerance, as defined by either of the following: 
a. A need for markedly increased amounts of opioids to achieve intoxication or desired effect. 
b. A markedly diminished effect with continued use of the same amount of an opioid.  
Note: This criterion is not considered to be met for those taking opioids solely under appropriate medical 
supervision. 
11. Withdrawal, as manifested by either of the following: 
a. The characteristic opioid withdrawal syndrome (refer to Criteria A and B of the criteria set for opioid 
withdrawal, pp. 547–548). 
b. Opioids (or a closely related substance) are taken to relieve or avoid withdrawal symptoms. 
Note: This criterion is not considered to be met for those individuals taking opioids solely under appropriate 
medical supervision.  
Opioid use disorder can be classified by severity as mild [meeting 2–3 criteria], moderate [4–5 criteria], or severe 
[6 or more criteria]. 
Source: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 
Arlington, VA, American Psychiatric Association, 2013 
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DSM-IV criteria for substance use disorders are still in common use, despite the flaws that led to their 
replacement in the DSM-5. For example, criteria specified in the Diagnostic and Statistical Manual for 
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) have been used to diagnose substance 
dependence, defined as “a syndrome characterized by a maladaptive pattern of opioid use, leading to 
clinically significant impairment or distress,” as manifested by at least 3 of the following and occurring 
in a 12-month period:  
1. Tolerance (marked increase in amount; marked decrease in effect);  
2. Characteristic withdrawal symptoms (substance taken to relieve withdrawal);  
3. Substance taken in larger amount and for longer period than intended;  
4. Persistent desire or repeated unsuccessful attempt to quit;  
5. Much time/activity to obtain, use, recover;  
6. Important social, occupational, or recreational activities given up or reduced;  
7. Use continues despite knowledge of adverse consequences (e.g., failure to fulfill role obligation, 
use when physically hazardous).  
When the FDA approved buprenorphine/naloxone, methadone, and naltrexone for the treatment of 
“opioid dependence,” DSM IV language was used. FDA approval and labeling of these medications has 
not yet reflected DSM–5 diagnostic changes. Under the DSM–5, most patients with “severe opioid use 
disorder” will be candidates for maintenance therapy with buprenorphine/naloxone, methadone, or 
naltrexone; some patients with “moderate opioid use disorder” may also be candidates.  
Not all physicians use the Diagnostic and Statistical Manual for Mental Disorders. The American 
Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction 
Medicine (ASAM) issued a consensus statement that distinguishes addiction from physical dependence. 
ASAM's diagnostic criteria for Addiction are listed below: 
 
ASAM Diagnostic Criteria for Addiction 
Addiction is a primary, chronic disease of brain reward, motivation, memory and related circuitry. Dysfunction in 
these circuits leads to characteristic biological, psychological, social and spiritual manifestations. This is reflected in an 
individual pathologically pursuing reward and/or relief by substance use and other behaviors. 
Addiction is characterized by:      
   a. Inability to consistently Abstain;      
   b. Impairment in Behavioral control;      
   c. Craving; or increased “hunger” for drugs or rewarding experiences;      
   d. Diminished recognition of significant problems with one’s behaviors and interpersonal relationships; and      
   e. A dysfunctional Emotional response                
Source:  American Society of Addiction Medicine. Public Policy Statement: Definition of Addiction, 2011  
                                      available at www.asam.org/for-the-public/definition-of-addiction 
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 Challenges in diagnosis:  
Pseudoaddiction – behavior with characteristics of addiction but rational, considering the patient's 
situation (e.g., inadequately treated chronic pain patients. May also apply to some patients who 
“self treat” underlying mental health disorders.)  (See Weissman 1989.) Pseudoaddiction should be 
ruled out before making a substance use disorder diagnosis. 
Physical dependence – may not be present in patients who have abstained for a period of time 
(e.g., incarcerated people), but severe opioid use disorder can still be diagnosed based on other 
criteria and past history of physical dependence. 
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Plan & Management 
 
PLAN OF CARE 
 
Major Recommendations: 
 Work collaboratively with patients to develop realistic, attainable, short-term goals for the 
management of opioid use disorders, including a personalized overdose risk reduction plan and other 
harm reduction strategies.   
 Determine treatment approach based on patient needs and preferences, available resources, and 
affordability. Also consider motivations for seeking care, previous treatment experience, duration of 
disorder at current severity, use of heroin vs. pills, method of use, source of opioids (prescribed vs. 
illicitly obtained), and co-occurring disorders.   
 Plan for close follow-up by a case manager and regular diagnostic evaluation with allowance for 
frequent and unscheduled visits. 
Rationale: The realities of homelessness (residential instability, extremely limited resources, lack of social supports) 
make adherence to a plan of care more difficult. Written goals and treatment plans that are realistic and change in 
response to changing circumstances are particularly important to assure appropriate care for these patients. Many 
homeless patients have obtained buprenorphine on the street and are familiar with its use prior to presentation at 
primary care clinics.  
Evidence: Expert consensus of practitioners experienced in homeless health care with expertise in primary care, 
addiction medicine, psychiatry, and harm reduction therapy.  
Sources: Alford 2007, ASAM 2013, Denning & Little 2011, Hwang 2011, Tsao 2012, Weissman 1989 
Factors to Consider in Deciding Whether/ What Kind of Treatment is Required: 
 Diagnostic criteria  Do patients meet DSM–5 criteria for opioid use disorder (specified on page 
16)? If so, how severe is their disorder? (How many criteria for opioid use disorder are met?)  
(Clinicians may find the Worksheet for the Diagnosis of Opioid Use Disorders in Appendix B 
helpful in determining severity level.) 
 Patient-centered goals  Work collaboratively with patients to develop a series of realistic, attainable, short-
term goals for the management of opioid use disorders, including overdose prevention and other harm reduction 
strategies (e.g., not using needles with drugs). The plan of care should include a personalized overdose 
risk reduction plan as a potential victim or witness of drug overdose/ poisoning. The care plan 
should also be sufficiently flexible to allow patients time to meet basic needs and legal/ 
employment obligations. Goals should be reviewed and revised periodically, consistent with 
changes in treatment, behavior, and living situation. It is essential that providers take time to elicit 
patient goals nonjudgmentally and tailor suggested treatments to these goals, recognizing that 
motivation toward a positive goal is a fundamental tenet of any behavior change. 
 Treatment approach consistent with patient needs and preferences  Work with patients to determine 
which treatment approach(es) within available options might best meet their individual needs and preferences. 
Know what treatment approaches are available in your community. Some communities offer only 
methadone or only buprenorphine for the pharmacological management of opioid use disorders.  
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Residential care and addiction counseling are not universally available. Recognize that successful 
outcomes of treatment for opioid dependence are strongly associated with treatment retention. 
Careful assessment of patient values and preferences at the outset will help to promote treatment 
adherence and prevent dropout.  
– For patients who do not want medication-assisted treatment or who find programs requiring 
abstinence as a prerequisite for treatment unsuitable or unrealistic, keep the door open and 
encourage harm reduction. Providers following principles of harm reduction must be prepared 
to work with patients who may be or appear to be under the influence of addictive substances. 
(A detailed discussion of harm reduction therapy is available in Denning & Little 2011, and on 
pp. 44–47 in Appendix A of this document.) 
– For patients considering MAT who don't want to discontinue heroin use, explain that 
methadone and buprenorphine may ‘block’ the effects of heroin but overdose is still a danger; 
that using buprenorphine immediately after using heroin can precipitate withdrawal; and that 
when heroin effects wear off, if the correct dose of opioid agonist medication is taken, patients 
should feel alert and not in withdrawal.  
– For patients who are very intoxicated: Patients who are intoxicated may not be able to process 
or remember complex discussions about treatment alternatives. Give clear, concise messages – 
e.g., “Come back tomorrow at [a specified time].” or “Come back when we can talk better.” As you walk 
them to the door, observe their gait to be sure they are safe. They may not remember signing a 
consent form or instructions, etc. A patient falling off the chair and not rousable could be 
dangerously intoxicated or overdosing; call 911. 
 Previous treatment experience  A history of unsuccessful treatment is not a contraindication to 
further treatment. Careful assessment will help the provider understand in what respects previous 
treatments were helpful or unhelpful. Changes in patient motivation and values can make a 
previously unsuccessful treatment effective or warrant a different treatment modality.  
 Duration of disorder  People with opioid use disorders of many years’ duration almost certainly 
need intensive, long-term interventions. Shorter-term disorders may respond to less intensive 
interventions. 
 Duration of disorder at current level of severity  Severity of opioid use disorders may vary over 
time. Obtaining information about past history of severe problems in a patient with seemingly mild 
current problems can be very helpful in decisions for selecting and monitoring treatments. 
 Heroin vs. pills  It is common for individuals to begin opioid use with prescription pills from their 
own prescription or a diverted source. In most localities heroin remains the least expensive, potent 
opioid available. As their opioid use disorder increases in severity and they experience financial and 
other losses, many individuals progress to heroin use. Risks of serious harm and severe opioid use 
disorders occur among both pill and heroin users. 
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 Injecting vs. other forms of use  There are multiple forms of opioid use. Cultural and individual 
factors as well as availability may determine drug choices and routes of administration. Both 
injection and noninjection (oral, intranasal) opioid use can result in severe opioid use disorders 
(dependence/ addiction) and other adverse consequences. Injecting drug users are at high risk for 
skin and soft tissue infections (cellulitis, cutaneous/ subcutaneous abscesses) and bloodborne 
pathogens (HIV, HBV, HCV).  
 Source of opioids  Treatment decisions and harm reduction strategies may be influenced by the 
source of opioids (medically prescribed, illicitly obtained, sharing with a partner/ family member/ 
friend). Nonjudgmental questioning may reveal factors that will influence treatment effectiveness. 
 Patient- vs. provider-identified adverse consequences of opioid use  Provider identified or socially 
recognized harms (overdose, infection, risky behavior, criminal justice problems) may not motivate 
the decision to seek treatment unless the patient is able to recognize those harms and how they may 
be reduced by a given treatment intervention. In general, people are more highly motivated to move 
toward a positive goal than away from a negative consequence.   
 Motivations for seeking care  Individuals with opioid use disorders seek care for a variety of 
reasons. Some present for treatment after witnessing the death of an acquaintance from overdose, 
violence, or illness related to drug use. Concerns about the effect of substance use on health, safety, 
or quality of life may not be the primary reasons for seeking care, however. The criminalization of 
drug abuse and social attitudes toward drug abusers can also influence the decision to seek care. 
Many homeless patients present for treatment as a requirement of the criminal justice system. 
Others seek treatment as a result of severe pressure from important people in their lives (family 
members, employers). Some patients present with atypical or unconventional motivations. Research 
has indicated that both internal and external motivators can be effective in engaging drug-
dependent individuals in treatment, although a client’s personal valuation of treatment and 
recovery is likely to be an important determinant of treatment retention, which is strongly linked to 
positive outcomes in the long term (Anglin1998, Prendergrast 2009). In reality, motivations are 
often complex and changing.  
 Existence of co-occurring disorders  Other substance use disorders, pain problems, mental health 
disorders, and cognitive impairment can also affect treatment choice. “Clients said to have co-
occurring disorders [COD] have one or more disorders relating to the use of alcohol and/or other 
drugs of abuse as well as one or more mental disorders. ... For most homeless clients with COD, 
the impact of substance use disorders and mental illness bears a direct relationship to their 
homeless status.” (CSAT 2005, TIP 42) The relationship to homelessness may or may not be causal, 
however, and is highly dependent upon financial and family resources available to the client.  
 Close follow-up by a case manager is recommended for homeless patients with opioid use 
disorders, with allowance for frequent and unscheduled visits (Alford 2007). 
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 Regular diagnostic evaluation is important to ensure that a diagnosis of opioid use disorder is not 
masking poorly managed chronic pain or other co-occurring disorders (Tsao 2012, Hwang 2011, 
Weissman 1989). 
(See the Treatment, Management section, pp. 28–49, for more detailed information about treatment 
alternatives, including advantages and disadvantages of different modalities for homeless patients.)
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Management of Opioid Use Disorders  
 Treatment options Explore the advantages and disadvantages of various treatment options with 
patients/clients, including use of medication-assisted treatment, side effects, risks and benefits.     
Be prepared to repeat this discussion, as needed, at subsequent encounters.  
 Harm reduction  Teach clients who are actively using addictive drugs to practice harm reduction, 
including overdose prevention and avoidance of exposure to bloodborne diseases. Teach clients 
who are currently abstaining to recognize signs and symptoms of relapse.  
 Drug-drug interactions  Explain possible interactions of methadone/ buprenorphine/ naltrexone 
with other medications (e.g., antiretroviral therapy for HIV infection) or drugs (alcohol, other CNS 
depressants) they may be taking, and whether particular foods, dietary supplements, or exercise might 
alter the physical or psychological effects of medications used for treatment of opioid use disorders.  
 Chronic brain disease  Explain how misuse of opioids and other addictive substances can change the 
brain. Help patients understand that opioid use disorder is a chronic disease that may never go away 
but can go into remission with appropriate treatment and ongoing attention to personal health.  
 Educational materials  Provide written educational materials in the first language of patients you 
serve, using simple terminology and large print with graphic illustrations to compensate for any 
visual limitations. Don’t presume that patients can’t read or understand written information just 
because they are homeless. 
Major Recommendations: 
 Review fundamental concepts of opioid use disorder management (treatment alternatives, side 
effects, risks and benefits); teach clients who are actively using opioids how to practice harm 
reduction; teach those currently abstaining to recognize signs and symptoms of relapse.  
 Provide opioid safety education to all patients with substance use disorders and to patients taking 
opioid analgesics on the effects of opioids, including the possibility of overdose and interactions of 
opioid agonists with other medications/ drugs of abuse.  
 Educate patients about overdose risks, recognition and response. Offer naloxone (if possible) to 
any patient undergoing tolerance changing events such as medically supervised withdrawal 
procedures or medication-assisted treatment induction. 
 Use tools such as motivational enhancement techniques and brief office-based counseling to help 
assess patients' level of readiness for behavioral change. 
Rationale: Understanding how to minimize risks associated with opioid use and involvement in self-management 
goal setting are matters of survival for opioid-dependent people who are homeless. Discussing risks and benefits of 
available treatment options with these patients can build trust, inspire hope, and foster readiness for behavioral 
change. Overdose prevention and response education is warranted by the alarming increase in the number of 
deaths from opioid overdose/ poisoning, particularly in marginalized populations.  
Evidence: Expert consensus of practitioners experienced in homeless health care with expertise in addiction 
medicine, overdose prevention, and harm reduction therapy. Sources: Doe-Simkins 2013, Edgington 2011, 
Morrison 2007, SAMHSA 2013, Walley 2013, Wheeler 2012, WHO 2013 
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Overdose Prevention and Response Education   
In response to an alarming increase in the number of deaths from opioid overdose/ poisoning, 
particularly in marginalized populations, homeless services providers recommend the following 
interventions to protect both patients with opioid use disorders and patients whose chronic pain is 
managed with opioids: 
 Opioid safety education  To all patients with a history of substance use and patients taking opioid 
medications for acute or chronic pain management, provide opioid safety education on the effects of opioids, 
including the possibility of overdose. Discuss risks for overdose, including: mixing different 
drugs/medications with opioids   
(such as alcohol, benzodiazepines, 
stimulants like cocaine or 
methamphetamine, antihistamines, 
sleeping pills); changes to their pain 
management regimen; resuming 
opioid use after a period of 
abstinence; comorbidities that may 
increase overdose risk (COPD, viral 
hepatitis, etc.); leaving substance use 
treatment or jail; the changing quality 
and strength of illicit substances; and 
the different strengths, function and 
duration of prescription opioids.  
 Overdose prevention & response 
education  Offer overdose education to 
any opioid-dependent patient undergoing tolerance changing events, such as medically supervised withdrawal 
procedures or medication-assisted treatment induction. (See inclusion criteria for opioid overdose 
prevention interventions, listed below.) Patients should receive education on overdose 
management; how to communicate with primary caregivers, friends, and family; high risk of 
accidental overdose/ unintentional poisoning from polysubstance use or medication errors; and 
what to do in the event of an overdose.  
Directly prescribe naloxone3 or refer patients to community based organizations that provide naloxone rescue 
kits and teach overdose response techniques.  
                                                 
3 Naloxone (Narcan®) is an opioid antagonist that is used to counteract life-threatening effects of opioid overdose on the 
central nervous system and respiratory system, allowing an overdose victim to breathe normally. It has been used routinely 
in Emergency Medicine for nearly 50 years. Naloxone may be sprayed into the nose or injected into a muscle, vein, or 
under the skin. It is a temporary drug that wears off in 20–90 minutes (Harm Reduction Coalition). “Naloxone is not a 
controlled substance as defined by federal or state law, but is a prescription drug subject to the general laws and 
regulations that govern all prescriptions in regular medical practice. Prescribing naloxone to ODUs is fully consistent with 
state and federal laws regulating drug prescribing.” (Temple University Law School's Project on Harm Reduction in the 
Health Care System) Detailed state-by-state information about which practitioners are authorized to prescribe or dispense 
naloxone and to whom naloxone may be legally prescribed or dispensed is available on the PrescribeToPrevent website. 
 
What You Need To Know About Opioid Overdose: 
     1.  Prevention – the risks:  
          Mixing substances 
          Abstinence- low tolerance 
          Using alone 
          Unknown source 
          Chronic medical disease 
          Long acting opioids last longer 
     2.  Recognition 
          Unresponsive to sternal rub with slowed breathing 
          Blue lips, pinpoint pupils 
     3.  Response – What to do: 
          Call for help (Dial 911). 
          Rescue breathe. 
          Deliver naloxone.  
          Continue rescue breathing.  
          If no response after 3-5 minutes, deliver naloxone again. 
         Stay until help arrives. 
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Make naloxone rescue kits readily available in non-locked areas of clinics and shelters, and train all staff how 
to use them to revive individuals experiencing opioid overdose. It is especially important to train outreach 
workers and shelter staff how to recognize and respond to drug overdoses experienced by homeless 
people. The expiration date of naloxone in on-site rescue kits should be checked regularly.  
Since 1996, laypersons who are at risk for overdose or likely to witness an overdose have been given 
naloxone “rescue kits” by community-based organizations like needle exchange programs. Over 
50,000 individuals have been given naloxone kits and trained to use them at the 200+ naloxone 
distribution programs in the United States, resulting in over 10,000 overdose reversals (Wheeler, 
2012). Communities with high rates of layperson possession of naloxone rescue kits have 
experienced a 46% reduction in fatal opioid overdose (Walley 2013). An international review of 
interventions for homeless persons discussed peers giving naloxone to others they see overdosing as 
a promising intervention to reduce drug-related deaths (Wright & Tompkins 2006). Recently, 
naloxone prescription programs have started in several health care settings throughout the United 
States, targeting people at risk for opioid overdose (Doe-Simkins 2013, CDC 2012 Feb). Access to 
naloxone varies by state. For more information, see www.prescribetoprevent.org.  
 Inclusion criteria for opioid overdose prevention interventions  Conduct overdose prevention 
education and consider providing naloxone rescue kits to patients who meet the following criteria:  
1. Taking high doses of opioids for long-term management of chronic pain. 
2. Receiving rotating opioid medication regimens (and thus at risk for incomplete cross-tolerance). 
3. Discharged from emergency medical care following opioid intoxication or poisoning. 
4. At high risk for overdose because of a legitimate medical need for analgesia, coupled with a 
suspected or confirmed history of substance abuse, dependence, or non-medical use of 
prescription or illicit opioids. 
5. Completing mandatory opioid detoxification or abstinence programs. 
6. Recently released from incarceration and a past user or abuser of opioids (and presumably with 
reduced opioid tolerance and high risk of relapse to opioid use). 
7. Engaged in any opioid use with known or suspected respiratory/renal/ hepatic/cardiac disease 
or HIV/AIDS. 
Sources: SAMHSA Toolkit for Prescribers, Albert 2011 
Some experts would recommend opioid overdose prevention intervention for all individuals taking 
opioids whether prescribed or not, and for loved ones of patients and concerned community 
members. For more information about inclusion criteria for opioid overdose prevention 
interventions, see: Dasgupta 2009, Leavitt 2010, Wermeling 2010, PrescribeToPrevent.org 
 Overdose response policy  Develop an organizational policy for responding to drug overdoses that occur on 
site. Train clinic and outreach staff to recognize signs of withdrawal and relapse.  
 Policy consistency with overdose prevention efforts  Examine existing program policies for overt or de 
facto contradiction with overdose prevention efforts. For example, are clients allowed to retain control of 
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a prescription medicine including a naloxone rescue kit that they may have acquired from another 
program? Do clients risk exclusion from program services for syringe possession, encouraging 
secretive drug use?  
 Counseling  Address overdose and any overdose-related trauma in client counseling. Adapt screening 
instruments to ask specifically about overdose-related trauma. 
 Commemoration  Recognize that many lives are lost to preventable overdose deaths and that 
patients may not have the space or opportunity to grieve these losses without shame or judgment. 
Consider creating a permanent space (memorial wall/ table used as a memorial space) for 
remembering homeless people who were lost as a result of drug overdose and other causes, and for 
celebrating staff and clients who save lives. 
 Resources  The Substance Abuse and Mental Health Administration (SAMHSA) has published an 
Opioid Overdose Prevention Toolkit designed to equip communities and local governments with 
material to develop policies and practices to help prevent opioid-related overdoses and deaths. This 
resource addresses issues for first responders, treatment providers, and those recovering from 
opioid overdose. Components of the toolkit, available online, are listed below:  
Information for Prescribers 
Safety Advice for Patients 
Resources for Overdose Survivors and  
Family Members 
Facts for Community Members 
Essentials for First Responders 
 
Education of Providers about the Treatment and Management of Opioid Use Disorders   
Despite extensive scientific evidence of their efficacy, FDA approved medications for the treatment of 
opioid dependence are underutilized, especially by general practitioners. The American Society for 
Addiction Medicine conducted a survey to determine the reasons why. Investigators concluded that 
primary factors preventing appropriate access to and utilization of these medications include the 
following: 1) few physicians trained to diagnose or treat opioid addiction; 2) unique legal and 
regulatory issues surrounding the provision and administration of these medications; and 3) 
restrictions on MAT utilization imposed by public and private insurers (pre-authorization 
requirements, limitations on dose and duration of dosing, and patient co-pays significantly different 
from those for medications used to treat other chronic diseases) (ASAM 2013) 
 Physicians working in homeless health care should be educated about patient selection for the treatment of severe 
opioid use disorder and how best to minimize and respond to drug misuse or diversion. Consider completion of 
training and certification to prescribe medication-assisted treatment of opioid dependence/addiction 
in an office-based setting.  
 Primary and specialty care providers serving marginalized populations should also attend trainings in addiction 
medicine to deepen their understanding of substance use disorders. Concepts such as ‘loss of control’ and 
‘compulsion to use’ enable the provider to distinguish severe substance use disorder from less harmful 
substance use. Many people who abuse opioids also abuse other addictive substances, such as 
methamphetamine and cocaine, for which there are no current pharmacological interventions. 
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Understanding the critical need for counseling in the management of addiction is essential, regardless 




 Goals  Short-term goals should be realistic and attainable given a patient’s self-reported coping skills 
and/or demonstrated resilience. 
 Behavioral change Use motivational enhancement techniques and brief office-based counseling to help 
engage patients and determine their readiness for behavioral change (HCH Clinicians’ Network 2009). 
Assessment of level of readiness to change guides any intervention for patients with opioid use 
disorders, including further education and support. Medical respite care programs can be an ideal 
setting in which to work with homeless patients on motivating readiness to change. Respite staff are 
expected be competent in understanding and recommending various avenues to change, including 
12-Step participation, harm reduction therapy, and medication-assisted treatment. (Edgington 2011).  
Motivational Interviewing (MI) is “a client engagement, motivational enhancement, and 
counseling process that has been widely used in mental health and substance abuse treatment 
settings and has been adapted for the needs of clients in homelessness rehabilitation (SAMHSA 
2013 TIP 55).” MI is useful to help patients explore and resolve ambivalence about behavioral 
change (Morrison 2007; HCH Clinicians’ Network 2000). Originally developed by William R. 
Miller and Stephen Rollnick (Miller & Rollnick 2002) to help problem drinkers, this counseling 
approach has been successfully applied to address a variety of behaviors that affect health, including 
smoking, other drug use, physical activity, and sexual practices.  
Brief counseling intervention The acronym FRAMES was coined to summarize the six elements 
that are critical to a brief intervention to change substance abuse behavior (Miller & Sanchez 1994):  
- Feedback is given to the individual about personal risk or impairment. 
- Responsibility for change is placed on the participant. 
- Advice to change is given by the provider. 
- Menu of alternative self-help or treatment options is offered to the participant. 
- Empathic style is used in counseling. 
- Self-efficacy or optimistic empowerment is engendered in the participant. 
A brief intervention consists of five basic steps that incorporate FRAMES and remain consistent 
regardless of the number of sessions or the length of the intervention (SAMHSA 1999):  
1. Introducing the issue in the context of the client's health 
2. Screening, evaluating, and assessing 
3. Providing feedback 
4. Talking about change and setting goals 
5. Summarizing and reaching closure 
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Treatment of opioid use disorders is necessary to prevent high morbidity and mortality, and has been 
proven to reduce harms related to opioid use. Successful treatment has been demonstrated to reduce 
HIV incidence, lower hepatitis B&C risk, minimize involvement with the criminal justice system, and 
decrease drug overdose rates (CDC 2002, Alford 2006, VA/DoD 2009, Altice 2011, White 2011, 
NIDA 2012 Apr).  
 
Special Considerations for Patients Experiencing Homelessness: 
 Lack of stable housing  Although instability and lack of social support are conditions of 
homelessness known to correlate with treatment failure, there is evidence that with case 
management support provided by the treatment program, medication-assisted treatment with 
buprenorphine is just as effective for people who are homeless as for those who are housed (Alford 
2007). Lack of stable housing is NOT a contraindication to medication-assisted treatment. Housing stability 
often determines level of care, with unsheltered persons ending up in residential treatment facilities 
or with more intensive monitoring than is required for persons with stable housing. 
Major Recommendations: 
 Offer medication-assisted treatment to any patient with an opioid use disorder. 
 Encourage use of nonpharmacologic interventions, whether patients are receiving medication-assisted 
treatment or not: harm reduction therapy, peer mentoring, peer support groups, acupuncture, and 
stable housing with access to supportive services including employment assistance. 
 Offer needle exchange and naloxone to individuals using injected opioids, to the extent permitted by 
law and available resources. 
 Encourage more physicians serving homeless and other disadvantaged populations to seek training 
and certification to prescribe buprenorphine. 
 Encourage more primary and specialty care providers serving homeless and other disadvantaged 
populations to collaborate and integrate care with addiction treatment programs, including 
methadone maintenance treatment and detoxification programs.  
 Develop more directly observed therapy (DOT) programs to monitor use and avoid misuse/ diversion 
of opioid agonist medications. 
Rationale: Choice of medication-assisted treatment for opioid use disorders depends on access to care, which is more 
limited for homeless than for stably housed persons. Although the feasibility of office-based MAT with buprenorphine 
has been demonstrated regardless of housing status, this medication is financially beyond the reach of many 
impoverished people living in states that have opted not to expand their Medicaid program to include childless adults. 
Limited numbers of physicians authorized to prescribe buprenorphine and the exclusion of physician assistants and 
nurse practitioners from prescribing privileges present additional barriers to care; in many areas, PAs and NPs are the 
only medical providers available to homeless people. Although methadone maintenance is less expensive and with 
comparable efficacy, access varies from community to community; waiting lists for admission to an opioid treatment 
program are long, and homeless people may not have the means to get to clinics at times when they are open.  
Evidence: Recommendations are based on expert consensus of practitioners experienced in homeless health care with 
expertise in primary care, addiction medicine, psychiatry, and harm reduction therapy.  
Sources: Alford 2007, Altice 2011, ASAM 2013, Herinckx 2008, Herinckx 2010, Hersh 2011, Hwang 2009, Kraybill & 
Zerger 2003, Martin 2013, SAMHSA 2013, Stancliff 2012, White 2011, Zevin 2011  
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 Lack of social support  Be aware that care provided to homeless populations may differ from the 
community standard of care. Longer duration of opioid use and lack of support from family or 
friends during treatment and recovery account for part of this discrepancy (Alford 2007). Treatment 
programs serving people with opioid use disorders who are homeless can mitigate their lack of social support 
with more comprehensive care management and peer support services. (See pp. 48–49 for examples.) 
“Social support is associated with lower rates of mental health problems, such as depression and 
suicidal ideation, fewer physical illness symptoms, decreased substance abuse, and less risky drug 
and sexual behavior among homeless individuals” (Hwang 2009). Provision of supportive services 
that address the myriad needs of these patients (medical, psychosocial, and material) is a vital 
component of any treatment modality.  
 High overdose risk  Regardless of the 
form of treatment for opioid use 
disorder, tolerance is altered upon 
engagement in treatment. This creates 
a potential paradox:  As a first step in 
addiction recovery, treatment can 
decrease overdose risk; but treatment 
can reduce tolerance and significantly 
increase the risk of fatal overdose for 
patients who cycle between abstinence 
and opioid use. Overdose risk also 
increases for persons utilizing alcohol or other prescribed/nonprescribed medications/drugs. Be 
aware that opioid agonist treatment is associated with a lower fatal overdose rate than heroin use, and that 
detox is associated with a higher fatal overdose rate than heroin use (WHO 2013, WHO 2009).   
 Therapeutic use of illicitly acquired opioid agonists Many homeless people with an opioid use 
disorder have had previous, often successful experiences with illicitly acquired buprenorphine 
and/or methadone. Exploring patients’ experience with illicitly acquired medications is a good opportunity to 
evaluate the appropriateness and anticipated benefits of these treatments. 
 Special issues for patients with co-occurring pain  For patients with co-occurring opioid use disorders and 
acute or chronic pain, a strategy that recognizes the need to treat both problems simultaneously to achieve a 
successful outcome should be implemented. Methadone and buprenorphine can be part of that strategy, 
as they have powerful analgesic effects, especially when used in split doses (Martin 2013, Alford 
2006). Non-medication-assisted therapies for both pain and addiction problems should also be 
pursued. Oral methadone and buprenorphine without naloxone in injectable or patch form are 
FDA approved for analgesia. Sublingual buprenorphine, labeled for addiction, is sometimes used 
off-label for treatment of chronic pain. Local insurance or pharmacy benefits may limit its use by 
requiring testing or counseling, etc. for coverage. Pharmacy benefit limits are especially significant 
for homeless patients using safety net services. Recognize that tramadol hydrochloride (Ultram®), 
an opioid mu receptor agonist prescribed for analgesia, has addiction potential similar to other 
"Recent periods of abstinence are a major risk factor for fatal opioid 
overdose. ... [T]he period immediately following release from prison and 
the period immediately following discharge from a detoxification facility 
pose a significantly elevated risk of overdose. The main causes of 
increased overdose mortality are loss of tolerance and erroneous 
judgment with respect to dosage when returning to opiate use following 
a period of abstinence. ...Many patients also cease opioid dependence 
treatment prematurely, which is associated with a return to out-of-
treatment levels of opioid overdose risk."  
                                                      — World Health Organization 2013 
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opioids but is often mistakenly used as if it did not. Be aware that low Vitamin D levels have been 
linked to high use of opioid analgesic medication by patients in chronic pain. Prescribing opioid 
analgesics for homeless patients with addiction disorders is challenging due to the frequent lack of 
subjective and functional improvement and the frequency of adverse outcomes (Wismer 2011). 
 Special issues for opioid-dependent pregnant women who are homeless  An exceptionally 
vulnerable population, these patients are at high risk for pregnancy complications and require 
immediate referral to both opioid treatment programs and high-risk obstetric programs. As noted 
by the American College of Obstetricians and Gynecologists, opioid use in pregnancy is not 
uncommon, and the use of illicit opioids during pregnancy is associated with an increased risk of 
adverse outcomes (ACOG 2012). The current standard of care for pregnant women with opioid dependence 
is referral for opioid-assisted therapy with methadone, but emerging evidence suggests that buprenorphine also 
should be considered. Induction on buprenorphine is generally done on an inpatient basis for safety 
reasons. If office-based maintenance treatment is indicated, buprenorphine alone should be used, not 
buprenorphine/naloxone. 
 
 Factors to Consider in Determining Appropriate Treatment Setting:  
1. Co-occurring conditions  Select a treatment setting with the greatest capacity to provide care for 
co-occurring conditions on site, recognizing that success often depends on effective treatment of 
the patient's other conditions.  
2. Suitability & location  Select a treatment setting suited to the patient's personality and coping 
skills that is easily accessible and (if possible) not in the same area where drugs of abuse were 
obtained.  
3. Residential programs  For patients who need a residential treatment setting, be aware that some 
residential programs are more supportive than others of MAT recipients. A number of residential 
programs deny admission to individuals receiving buprenorphine or methadone maintenance 
treatment. Some therapeutic communities have a harsh “boot camp” atmosphere and punish 
residents for undesirable behavior. Many clients do not do well in these punitive settings. 
Providers may need to educate staff in residential programs and halfway houses that medication-
assisted treatment with methadone or buprenorphine is not equivalent to the use of illicit 
substances.  
4. Treatment needs  Considerations in selecting a medication-assisted treatment setting should 
include whether or not the patient needs detoxification, is a candidate for maintenance 
treatment, and/or requires opioid analgesia. 
5. Level of care  Patient Placement Criteria guidelines available from the American Society of 
Addiction Medicine (ASAM) can help with level of care determinations. Some state agencies use 
them for placement. The recently released edition includes adjustments for homelessness. In 
reality, treatment setting is usually determined by available local resources and patient 
preferences. Substance abuse counselors can be helpful in discussing treatment options and 
available programs with patients before linking them to care. 
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Medication-Assisted Treatment for Opioid Use Disorders 
 
“Medication-assisted treatment (MAT) is the use of pharmacological medications in combination with 
counseling and behavioral therapies to provide a ‘whole patient' approach to the treatment of substance 
use disorders (SAMHSA).” Currently there are three FDA approved medications for the treatment of 
opioid dependence: methadone, buprenorphine/naloxone, and extended-release injectable 
naltrexone. These medications are available 
for use in detoxification or maintenance 
modalities.  
Methadone is an opioid agonist that is 
available for treatment of opioid use 
disorders primarily in strictly regulated opioid 
treatment program settings. Buprenorphine is 
a partial agonist with very strong affinity for 
the mu receptor that is intended for 
sublingual administration. In the U.S., it is 
combined with naloxone to deter the risk of abuse via injection. Buprenorphine alone (Subutex®) is 
used in situations of lower risk of misuse or diversion such as supervised detoxification, and in 
pregnancy or in situations where it is the only available option due to cheaper price. The combination 
of buprenorphine/naloxone (available as Suboxone® film or generic buprenorphine/naloxone 
combination tablets) is more often used for longer term maintenance treatment. (ASAM 2013, Yokell 
2011) Buprenorphine is available in office-based settings from specially trained physicians who have 
received a special DEA certification.4 Oral and injected naltrexone formulations are available for 
relapse prevention to patients who are abstinent from opioids for seven days. Extensive information 
about these modalities is available in ASAM 2013, Yokell 2011, VA/DoD 2009, WHO 2009, and in 
several reviews on these topics: Bart 2012, NIDA 2012 Apr, ONDCP 2012, Preda & Dunayevich 2013, 
White & Mojer-Torres 2010.  
Detoxification  
“Detox” or detoxification usually refers to the initial necessary step of assisting a patient through a 
period of withdrawal. Withdrawal from opioids is intensely unpleasant for individuals with opioid use 
disorders. Although it is not usually associated with mortality, withdrawal from opioids without 
                                                 
4
 “The use of buprenorphine for the treatment of opioid addiction is governed by the federal Drug Addiction Treatment 
Act of 2000, commonly referred to as ‘DATA 2000’ (Public Law 106-310, Title XXXV, Sections 3501 and 3502). This 
legislation ... allows physicians to treat opioid addiction with FDA-approved controlled drugs in office-based settings. 
Specifically, DATA 2000 allows physicians to use buprenorphine and other controlled substances in CSA Schedules III, 
IV, and V, which have been approved by the FDA for the treatment of opioid dependence, to treat patients in office-based 
settings, provided certain conditions are met. DATA 2000 thus has enlarged treatment capacity by lifting the requirement 
that patients who need opioid agonist treatment can receive such treatment only in specially licensed opioid treatment 
programs (OTPs), often referred to as ‘methadone clinics’.”  Source: Federation of State Medical Boards. Model Policy on 
DATA 2000 and Treatment of Opioid Addiction in the Medical Office, April 2013. 
“Methadone and buprenorphine used as detoxification 
medications can suppress withdrawal symptoms and curb 
cravings. When used as maintenance medications the 
suppression of withdrawal and craving helps to reduce non-
medical opioid use. Naltrexone can only be administered to 
fully detoxified patients, but as a maintenance medication it can 
essentially eliminate the rewarding effects of self-administered 
opioids, thereby dramatically reducing use.”  
              — American Society of Addiction Medicine (ASAM 2013) 
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medical supervision can be potentially life threatening for those with severe coronary artery disease. 
Increased demands on the heart due to elevated pulse and blood pressure during withdrawal could 
precipitate a myocardial infarction resulting in death. Moreover, “abrupt discontinuation of opioids in 
an opioid-dependent pregnant woman can result in preterm labor, fetal distress, or fetal demise 
(ACOG 2012).” Detox may be an initial step in treatment but alone has very poor efficacy for achieving 
successful long-term outcomes, which places patients without additional treatment or therapies at very 
high risk for overdose.  
Detox begins with a medical assessment, admission physical exam, vital statistics monitoring, and in 
some models, management of already prescribed medications to provide relief from withdrawal 
symptoms during detoxification. Because medications used for detoxification are often abused if not 
used in a controlled environment, they may be prescribed only for patients entering a recognized detox 
and rehabilitation program. For patients requesting medication to “help with [opioid] detox,” well-
meaning providers have been known to prescribe codeine, hydrocodone, or a benzodiazepine. (Note: 
Buprenorphine, when prescribed by a qualified physician, is the only opioid currently approved for the treatment of 
opioid dependence in an office-based setting; it is illegal for a physician to write a prescription for any other opioid 
for the treatment of opioid dependence) These medications are not indicated for treatment of opioid use 
disorder, and providers should use caution in prescribing them for symptomatic treatment of 
withdrawal symptoms in patients with opioid dependence.  
Quetiapine (Seroquel) can be a helpful symptomatic treatment for agitation associated with withdrawal, 
but it also has abuse potential and a street value. Although clonidine helps with autonomic withdrawal 
symptoms (increased blood pressure, sweats, goose bumps), there is the potential for hypertensive crisis if 
it is overused and then abruptly stopped. Treatment with clonidine is limited to two weeks for this 
reason. Promethazine PO or suppositories can be used to alleviate nausea/vomiting, and loperamide is 
useful to stop diarrhea during withdrawal from opioids. 
Factors Favoring Detox / Short-term Treatment with Tapering  
(This could include non-opioid symptomatic treatment “kickpack,”5 methadone detox with taper over 
21 days or a similar period, and buprenorphine stabilization and taper over days to as long as 1 year.) 
1. Short period and moderate degree of opioid use disorder 
2. Non-injection forms of use 
3. No history of prior treatment with relapse 
4. Strong support from family, community, or substance abuse treatment program 
5. Patient and provider understanding that this type of treatment is often not effective in achieving 
long-term abstinence 
6. Patient preference   
                                                 
5 A "kickpack" refers to nonopioid medications used for relief of withdrawal symptoms (e.g., quetiapine for agitation, 
clonidine for autonomic symptoms, promethazine for nausea, loperamide for diarrhea). See above for risks associated with 
these medications. 
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Advantages of detox/ short-term treatment: 
 Affordability  Maintenance treatment following detoxification may not be available due to a 
patient’s insurance status/lack of insurance or ability to pay cash.  In some states, methadone is 
not a covered benefit under Medicaid. Methadone maintenance is not a covered benefit under 
Medicare. Buprenorphine coverage is limited in some State Medicaid programs, and is often 
financially out of reach due to its higher cost and lack of prescribers who accept Medicaid or 
even regular insurance. Methadone clinics often have a sliding fee schedule; but if clients can’t 
pay their fees, they are detoxed only. In many areas, clinicians are still providing MAT on a cash-
only basis, drastically limiting a homeless patient’s ability to afford maintenance treatment.  
 Availability Limited access to authorized providers of maintenance treatment makes detox the 
only available treatment alternative for many homeless people with opioid dependence. Access 
to OTP’s providing methadone maintenance may be limited and waiting lists are long in some 
areas. Office-based treatment for opioid dependence can only be provided by credentialed 
physicians, and buprenorphine is the only medication currently approved for office-based 
treatment (VA/DoD 2009), except as part of isolated studies of medical maintenance (White 
2011). DATA 2000 implies that there may be other FDA-approved medications for this 
indication, but none has been added as of February 2014. In order to prescribe buprenorphine, 
physicians must complete a training course and receive a waiver granted by the Drug Enforcement 
Administration (DEA) (ONDCP 2012). Only a limited number of patients can be served by an 
authorized buprenorphine prescriber (30 in the first year, 100 in follow-up).  
Provision of medication-assisted treatment with buprenorphine has been slow to catch on in the 
medical community (Hersh 2011, Stancliff 2012). Clinical follow-up for stabilization and 
maintenance therapy can be burdensome and unpredictable for providers already overwhelmed 
with meeting primary care needs of an underserved population. Lack of experience with this 
treatment modality prevents clinicians from appreciating its efficacy. Prescribing limitations for 
midlevel providers exacerbate the lack of provider availability. Consequently, treatment following a 
detox stay simply may not be available to underserved populations. 
 Bridge to long-term addiction treatment  Comment from one consumer: “Now that BUP is 
offered, people are staying in detox long enough to make them ready to enter an addiction 
treatment and recovery program.” 
Disadvantage:   
 High risk of lethal overdose Detox and short-term treatment may leave patients at high risk of 
overdose death by lowering tolerance in those with high risk of relapse to drug use at their 
previous tolerated dose (Zevin 2011).  
Detox and Maintenance Treatment Considerations: 
 Treatment efficacy  Use of methadone and buprenorphine to treat severe opioid use disorders 
gives better results than medication-free treatment in almost all randomized controlled studies 
(Mattick 2009, Jerry & Collins 2013). In long- term studies of chronic heroin users, less than 10%–
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20% achieve abstinence without methadone or buprenorphine maintenance treatment, and relapse 
to opioid abuse occurs in more than 80% without long-term use of methadone or buprenorphine, 
regardless of what other kinds of treatment patients are receiving (Ball 1991, Sees 2000, Kakko 
2003).  Methadone and buprenorphine significantly reduce mortality rates, IV drug use, crime, 
HIV infection, and relapse, while increasing employment and improving health status and social 
function (CDC 2002, Altice 2011, NIDA 2012 Apr). Nevertheless, the consumer community has 
mixed feelings about both agents (White 2011).  
 Harm reduction vs. harm production  No medical intervention is entirely without the potential 
for adverse effects. Both methadone and buprenorphine have well-established safety records but 
also the potential to cause harm. In each case a careful evaluation must be done weighing the 
benefits and harms of medication-assisted modalities. Consequences of not treating must also be 
considered. Due to the frequency of dire consequences in patients with untreated severe opioid 
disorders, it is often appropriate for clinicians to offer these treatments to patients who have some 
increased risk of adverse effects. Efforts must be made to make sure that patients are aware of these 
issues and give informed consent. 
 Combating common myths Unfortunately many myths are present as street lore (and even among 
professionals) that discourage opioid users from considering maintenance treatment. The most 
prevalent of these is the idea that use of buprenorphine or methadone is substituting one addiction for 
another. This can usually be combated by explaining what is meant by addiction in medical terms 
and showing the much better health outcomes from MAT compared to street drug use including 
normalization of various metabolic, neurological, and immunological states. Another common 
myth is that withdrawal from methadone or buprenorphine is worse than withdrawal from heroin. 
Withdrawal is different from these longer half-life drugs than from short half-life drugs but is 
usually less acutely severe. It is also commonly heard that methadone “eats up the bones.” Explaining 
that opioid use may affect testosterone in men, that vitamin D levels are commonly low in opioid 
users, and that these conditions are correctable is usually helpful.  
 Addiction counseling The federal application for a waiver that permits a trained and qualified 
physician to prescribe buprenorphine for outpatient treatment of opioid dependence requires 
providers to ensure that patients engage in addiction counseling. If not offered within the 
prescribing provider’s practice, there must be evidence that the provider has the ability to refer and 
that patients engage in counseling. Research suggests that medication-assisted treatment of opioid 
use disorders combined with effective evidence-based counseling provides outcomes superior to 
either intervention by itself (McClellan 1993 Apr, as cited in ASAM 2013). However, lack of access 
to/ interest in/compliance with counseling is often a serious barrier to medication-assisted treatment for opioid 
use disorders. Access to addiction counseling may be especially difficult for people experiencing 
homelessness due to lack of transportation, lack of health insurance, lack of availability and 
accessibility of (limited) community resources, and if employed, lack of time or fear of loss of income 
from taking time away from work. 
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Recent studies by Schwartz and Fiellin found that counseling added no significant benefit to opioid 
agonist treatment with methadone or buprenorphine, concluding that limited availability of drug 
counseling services should not be a barrier to initiating MAT alone. Nevertheless, many 
practitioners experienced in the care of homeless people contend that treatment of opioid 
dependence in this population optimally includes counseling and provision of/referral to other 
needed medical, psychological, and social services (HCH Clinicians' Network 2006 Oct).  
Counseling can be provided by various service providers, including medical providers, nurses, mental 
health professionals, and substance abuse counselors. In homeless health care settings, the most 
effective counseling may be from an available member of the staff whom the patient trusts, even if the 
staff member is not an addiction specialist. Professional counseling is often supplemented by peer 
mentorship or coaching, featuring a “one-on-one relationship in which a peer leader with more 
recovery experience than the person served encourages, motivates, and supports a peer who is seeking 
to establish or strengthen his or her recovery” (CSAT 2009). The important role of formal and 
informal peer mentors is increasingly recognized as a component of successful treatment programs. 
(See p. 49 for more information.) 
Factors Favoring Outpatient / Office-Based Maintenance Treatment with Buprenorphine 
1. Support from significant other or family 
2. Lack of significant other and family members 
who are using substances or are chaotic and 
destabilizing 
3. Realistic expectations 
4. Existing relationship with a primary care 
physician or psychiatrist willing and licensed to 
prescribe buprenorphine 
5. Ability to understand and adhere to program 
policies and procedures  
6. Complying with institutional rules may be 
difficult for patients with opioid use disorders, 
especially when this co-occurs with cognitive 
disorders, unstable housing, and psychiatric 
disorders. Some successful programs employ flexibility based on patients’ needs.   
7. Increased flexibility of office-based settings compared to opioid treatment program (OTP) settings 
may actually favor patients who have difficulty with rigid rules. 
8. Availability of intensive case management services, especially during initial treatment period 
(Alford 2007) 
9. Multiple unsuccessful attempts at treatment do not necessarily preclude future success. 
10. Lack of contraindications to buprenorphine therapy, such as: 
“There is substantive research evidence that long-
term, positive outcomes (both at the patient and 
system-level) can be achieved in primary care and 
other outpatient settings with buprenorphine 
maintenance treatment, even for traditionally 
vulnerable patient populations (i.e.. those who have 
HIV, are homeless or marginally housed, or are 
extremely low SES (Alford et al, 2007; Parran et al, 
2010; Sullivan et al, 2008; Fiellin et al, 2008; Korthuis 
et al, 2011; Stancliff et al; 2012).” 
— ASAM 2013, The Effectiveness of Pharmacotherapies for 
the Treatment of Opioid Disorders: A Systematic Review 
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Medical contraindications: 
 Need for other opioid analgesic for pain management.  
- Buprenorphine acts as a blocker to other opioids and may interfere with analgesic effects of 
other opioid analgesics. 
- Note: Some patients with chronic pain and addiction can be managed with buprenorphine, 
as it works as a strong analgesic when used in divided doses. 
 Acute medical conditions needing stabilization 
- Note: Patients may be appropriate for buprenorphine therapy after stabilization, such as 
upon hospital discharge. 
Psychiatric contraindications: 
 Too disorganized to take medication regularly  
-  Note: Opioid dependence (especially heroin dependence) requires a fairly high level of 
organization for most patients, although the effort required may create chaos in other areas 
of life. Patients who are organized enough to maintain an opioid dependence usually are 
organized enough to take buprenorphine when adequate support is provided. 
 Suicidality or other acute conditions needing stabilization 
- Note:  Patient may be appropriate for buprenorphine therapy after stabilization, such as at 
hospital discharge. 
Substance-related contraindications: 
 Unsupervised / uncontrolled benzodiazepine (BZD) use. Buprenorphine overdose when 
combined with benzodiazepine use has been rare in the U.S. experience but was reported in 
France with injection BZD use. 
 Other nonmedical sedative hypnotic use—e.g., carisoprodol (Soma) 
 Any alcohol use is a potential issue because it depresses CNS function and can increase risk for 
overdose. 
 Note: Recognize that risks associated with discontinuing MAT are very high. Alternatives may be 
unavailable, unacceptable, or inappropriate for the management of opioid addiction. Weigh risks and 
benefits of discontinuing versus continuing buprenorphine maintenance. (Using heroin or methadone with 
benzodiazepines or alcohol is more dangerous.) 
11. Lack of contraindications to office-based treatment, such as: 
 No safe place to keep medication.  
 Patient unable to create safe home environment and prevent risk of children's exposure to 
medication.  
 Patient at very high risk of diverting medication. 
 Note: These safety considerations may be surmountable with programmatic adaptations – e.g., 
intensive case management, prescribing at variable intervals, and bringing treatment to the 
patient by providing directly observed therapy in shelters. 
12. Patient values and preference 
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Advantages of buprenorphine maintenance treatment: 
 Demonstrated efficacy in eliminating withdrawal - usually effective within minutes to hours of 
first dose, with most patients not experiencing any withdrawal after 2–3 days. 
 Demonstrated efficacy in reducing craving for opioids; may reduce alcohol use (Nava 2008); 
does not change craving for other drugs. 
 Effect of blocking other opioids helpful in discouraging patients from trying to use when on 
buprenorphine. 
 Proven safety over long-term use. 
 Comparable efficacy in office-based settings regardless of housing status (Alford 2007). 
 Ceiling effect for overdose: 
- Pharmacology studies suggest that buprenorphine alone or combined with other opioids 
probably has less risk of overdose than methadone. It is practically impossible to overdose 
on buprenorphine alone or buprenorphine combined with other opioids. (CSAT 
Buprenorphine Information Center) 
- Fatal overdoses of buprenorphine combined with other sedatives, including 
benzodiazepines and alcohol, can still occur, however.  
 Can be helpful for individuals with severe opioid use disorder and pain when used in split dose. 
- Most patients can dose once a day and have full effects; some patients benefit from split 
dose, which is logistically easy to accomplish. 
- Patients describe the experience of taking buprenorphine as “feeling normal” (i.e., not 
feeling “under the influence”). Some patients, especially those with severe anxiety / complex 
PTSD, cannot tolerate what normal feels like to them. Those who have used short-acting 
opioids such as heroin for years have conditioned themselves to fear alertness, which has 
come to mean that they will shortly be in withdrawal (within 2–4 hours). They gradually 
learn that it is safe to be alert if they are on a long-acting opioid. 
- Adaptable to patients experiencing homelessness: Ability to prescribe/ dispense as frequently 
as daily, or as infrequently as monthly or less often is very helpful to people with variable 
capacity to manage and store medications and a high degree of transience. Wide availability of 
buprenorphine nationally is helpful to populations that may be transient. 
Disadvantages: 
 Initial induction can be challenging; requires patient to abstain from opioids for period of time to 
avoid “precipitated withdrawal.” Some patients cannot tolerate even short periods of withdrawal. 
 Changing from long-acting opioids—especially methadone—may require tapering methadone 
dose over a long period and then 48 hours or more of abstaining before it is safe to start 
buprenorphine induction. “Transfers are possible between a >30-60 mg/day of equivalent 
methadone dose (high-dose transfer), although dose reduction to ≤ 30 mg/day followed by a 
normal transfer is preferred.” (National Alliance of Advocates for Buprenorphine Treatment's 
Suboxone Dosing Guide) 
 Some people need more structure than outpatient buprenorphine prescribing can provide. 
 Health Care for the Homeless Clinicians’ Network  
ADAPTING YOUR PRACTICE: 
Recommendations for the Care of Homeless Patients with Opioid Use Disorders  
38 
Elements of Planning for Office-Based Treatment with Buprenorphine: 
If the patient is selected for office-based treatment with buprenorphine, consider whether detox alone or 
maintenance treatment is warranted. There is no imperative to decide in advance whether to use 
detoxification or maintenance. Patients can be treated with buprenorphine as long as necessary, taper at 
any point, and be readmitted if a relapse occurs. However, maintenance treatment has better outcomes.  
Cost considerations:  “In general, buprenorphine-naloxone (Suboxone) medication costs are 
approximately five times more than methadone (~$3.50–$5.00 per dose versus~$0.50–$1.50 per dose); 
the administration costs are approximately comparable though in very different settings (dedicated 
methadone clinic versus office setting); and the clinical effects on reductions of opioid use and opioid 
use-related health and social problems are quite comparable.” (ASAM 2013 Report III by Chalk et al., 
p.66) Buprenorphine/naloxone medication ($148/$260 for 30 generic tablets 2–.5 mg/8–2 mg) at a 
national retail pharmacy in December 2013) is more expensive than methadone but less expensive than 
extended-release injectable naltrexone and can be administered by specially trained generalist 
physicians in a range of clinical settings. Maintenance treatment following detoxification may not be 
available to homeless patients, however, due to lack of insurance or resources to pay cash. 
As of June 2013, every state Medicaid program covered buprenorphine/naloxone as an outpatient 
pharmacy benefit, either in the film form (Suboxone®) or in the generic sublingual tablet formulation. 
Nevertheless, there are significant variations among the states in the range and duration of covered 
benefits and prior authorization requirements, which often create a “de facto denial of access.” (ASAM 
2013, Report I by Rinaldo & Rinaldo) Buprenorphine may be prohibitively expensive for patients who 
are not eligible for Medicaid (e.g., live in states that have opted not to expand their Medicaid program 
to cover single childless adults with income at or below 138% of poverty, as authorized by the Patient 
Protection and Affordable Care Act of 2010). In 2011, 79.3% of homeless patients served by HCH 
clinics had incomes at or below 100% of poverty, and 62.4% had no health insurance at all (HRSA 
UDS 2011, HCH grantees). For uninsured patients who do not qualify for Medicaid, patient assistance 
options are extremely limited. Thus, access to MAT with buprenorphine/naloxone may be limited by 
cost and lack of trained prescribers who accept Medicaid or even private insurance (Murphy 2014). In 
many areas, clinicians are still providing medication-assisted treatment on a cash-only basis, drastically 
limiting a homeless patient’s ability to afford maintenance treatment.  
Retail Costs of FDA Approved Buprenorphine Products at a National Retail Pharmacy Chain 
Drug Name Active Ingredients Dosage Form/Route Amt Strength Price 
buprenorphine hydrochloride and 
naloxone hydrochloride (generic) 
buprenorphine hydrochloride; 
naloxone hydrochloride 




























buprenorphine hydrochloride Tablet/ Sublingual 
30 
30 




Subutex® (Brand name) buprenorphine hydrochloride Tablet/ Sublingual 
30 
30 




   Sources: FDA & CVS Pharmacy, 12/13/2013 
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Beginning treatment  If buprenorphine maintenance treatment is chosen, plan alternatives for 
initiating treatment, called induction. The patient must be in withdrawal before maintenance 
treatment is initiated. “The goal of the induction phase is to find the minimum dose of buprenorphine at 
which the patient discontinues or markedly diminishes use of other opioids and experiences no withdrawal 
symptoms, minimal or no side effects, and no uncontrollable cravings for drugs of abuse.” (CSAT 2004)  
Determining dosage:  Induction is begun by administering small doses of buprenorphine to determine 
at what point cravings and symptoms of withdrawal abate, in order to calculate the total daily dose 
needed. Procedures for induction are covered in the DEA-mandated physician training. The standard 
protocol starts with a 2/0.5 mg strength tablet, with subsequent gradual up-titration. Because a number 
of opioid-dependent homeless patients have used buprenorphine illicitly before seeing a prescribing 
physician, a more rapid induction may be successful by taking their experience into consideration. 
However, such patients may ask for a high dose because buprenorphine has a street value; so observe 
them after they have taken the suggested dose to be sure that it is safe for them. Health Care for the 
Homeless providers report beginning patients on a minimum daily dose (8 mg), but increasing the 
dosage if they experience any cravings whatsoever, to avoid relapse.  
Determining induction setting – in-office (supervised) vs. “home”(unsupervised):  Availability of staff 
for induction days in primary care settings, the patient’s comfort level using the medication for self-
induction, availability of staff for on-call contact during induction, and previous ongoing use of 
methadone (tissue stores) are important considerations in determining where induction for 
buprenorphine maintenance treatment will occur. Many patients who are opioid dependent and are 
using opioids just to avoid getting sick have tried buprenorphine purchased on the street, and thus are 
familiar with its use. For such patients, the main risk of using unsupervised induction is precipitated 
withdrawal. A more serious concern is about precipitating withdrawal in patients who are 
buprenorphine naïve. For patients less motivated to pursue maintenance therapy, there is higher risk 
for diversion with unsupervised induction. Regardless of setting, the induction period is an ideal time 
to discuss overdose risk due to potential tolerance changes, rotating from one opioid to another, and 
potential for polydrug use during this period. 
Problems getting patients induced:  It is essential for patients to be in withdrawal before the induction process 
begins. Buprenorphine binds very tightly to the mu opioid receptor and will displace any other opioid 
from the receptor, precipitating an immediate withdrawal reaction. (The naloxone component of 
Suboxone is not relevant to this.) Those who are not already in withdrawal will become ill almost 
immediately. Some patients who have spent many years trying to avoid the acute discomfort associated 
with withdrawal may have trouble allowing themselves to experience it purposely. Opioids can be 
detected in urine for up to 72 hours. A patient can be in withdrawal with a positive opioid screen; if 
there are no opioids in urine toxicology results, question your diagnosis and/or the test results. 
Understand what tests your toxicology lab uses, how to interpret them, and whom to contact for expert consultation. 
A patient who has left an abstinence treatment program or has been discharged from jail but has not 
yet started using opioids will not be in withdrawal. It is possible to start these patients on 
 Health Care for the Homeless Clinicians’ Network  
ADAPTING YOUR PRACTICE: 
Recommendations for the Care of Homeless Patients with Opioid Use Disorders  
40 
buprenorphine without fear of inducing precipitated withdrawal. These are patients for whom 
initiation of medication-assisted treatment may be most critical. 
Barriers to “on demand” enrollment and induction:  Commonly, homeless patients come to clinics in 
withdrawal and want to get started on buprenorphine immediately. Treatment on demand may be 
necessary for patients who have little control of their location. Guidelines outline a number of 
preliminary steps before buprenorphine therapy can be started (history and physical, labs, and 
documentation of opioid dependence, the most important requirement), which can make “on demand” 
enrollment and induction challenging. Documenting opioid dependence can be done at one visit, 
however; and induction plans can be made during the same visit, including giving the patient a small 
prescription to fill and bring back for observed ingestion. If patients must return for induction on another 
day, consider providing a motel voucher or respite bed the night before, in order to maximize the chances of the 
patient's coming to the clinic in withdrawal. HCH clinicians in Colorado use this strategy prior to important 
clinical procedures (e.g., colonoscopies), and appointments (e.g., Social Security) with very good results. 
Factors Favoring Treatment in an Opioid Treatment Program [OTP] with Buprenorphine  
(In some areas buprenorphine is available from narcotic treatment programs as an alternative to 
methadone.) 
1. Patient would benefit from daily observed dosing.  
- Benefit may also be primarily to the community or family of patients at high risk of diverting 
medication or with home settings in which it is impossible to keep medication away from others 
it could harm. 
2. Contraindications to office-based treatment 
3. Patient is able to attend OTP at location and specific hours when it is open.  
- Homeless patients and those in rural settings may not have the means to get to the clinic at 
specific times. 
- Many OTP’s were specifically designed with the needs of working people in mind. (Not all 
homeless people are regularly employed.) 
4. Ability to understand and adhere to program policies and procedures 
- OTP’s generally have strict guidelines based on state and federal regulations. 
5. Patient values and preference 
Advantages of buprenorphine in OTP :  
 Ability to establish a daily routine for taking medication;  
 Decreased worry about losing or having medication stolen, lost, or diverted in other ways; 
 A strong connection to counseling; and  
 Other advantages of a highly structured program. 
Disadvantages:: 
 Limited availability of such programs.  
 Many patients wish to avoid associating with and congregating around other people with a 
history of addiction.  
 Many people are unable to tolerate a highly structured environment. 
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Factors Favoring Treatment in an Opioid Treatment Program with Methadone  
Methadone maintenance in an opioid treatment program has a long track record of success and was 
the only effective treatment available for severe opioid use disorders for decades. Detailed information 
about methadone maintenance is available at: VA/DoD 2009, CSAT 2005 TIP 42, Bart 2012, Mattick 
2009, ONDCP 2012, Preda & Dunayevich 2013, and White & Mojer-Torres 2010. 
1. Patient would benefit by daily observed dosing 
- Benefit may also be primarily to the community or patients family such as patients with a high 
risk of diverting medication or home settings in which it is impossible to keep medication safe 
from others it could harm. 
2. Patient is able to attend OTP at location and specific hours when it is open. 
- Homeless patients and those in rural settings may not have the means to get to the clinic 
location at specific times. 
- Many OTP’s were specifically 
designed with the needs of working 
people in mind. (Not all homeless 
people are regularly employed.)  
3. Ability to understand and adhere to 
program policies and procedures 
- OTP’s generally have strict 
guidelines based on state and 
federal regulations 
4. Lack of contraindications to 
methadone treatment 
5. Patient values and preference  
Advantages of methadone in OTP : 
 Ability to establish a daily routine 
for taking medication  
 Decreased worry about losing or 
having medication stolen or lost or 
diverted in other ways  
 Strong connection to counseling and other advantages of a highly structured program  
Disadvantages:  
 limited availability of such programs.  
 Many patients wish to avoid associating with and congregating around other people with a 
history of addiction; and many people are unable to tolerate a highly structured environment. 
 Some patients may require high doses for full effect.  
 Does not change craving for other drugs 
The sedating and anxiolytic opioid effects of methadone are considered an advantage by some 
patients and a disadvantage by others. 
 “Currently, no standards exist that guide clinicians to match 
patients with methadone treatment. Kleber (2007) suggests that 
methadone may be more suitable for patients with the following 
characteristics: 
 unstable lifestyle (e.g., homeless or marginally housed) 
 would benefit from the structure of regular attendance in a  
  dispensing situation 
 would benefit from the wider range of services available at a   
   comprehensive methadone maintenance program 
 few financial resources or uninsured or underinsured 
Additionally, patients who lack social support might also benefit 
from the more systematized environment that is characteristic of 
the methadone treatment paradigm. Pinto and associates (2010), 
however, emphasize that the decision as to which medication is 
prescribed is based on understanding the known pharmacology of 
the drugs, patient characteristics and preferences, and ultimately 
on the clinicians’ opinions.” 
—  ASAM 2013, The Effectiveness of Pharmacotherapies for the  
 Treatment of Opioid Disorders: A Systematic Review, Appendix 1, p. 32  
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Elements of Planning for Methadone Maintenance Treatment (MMT): 
Cost considerations:  MAT with methadone is the least expensive alternative for medication-assisted 
maintenance treatment; medication costs average $30 –$40 per monthly dose, and total costs range 
from approximately $6,000 to $12,000 per year, depending upon the nature and frequency of 
counseling and social services provided. “Various studies have seen clinically and statistically significant 
reductions in opioid use and opioid use-related incidence of infectious diseases and crimes with averted 
costs ranging from two to four times the costs of methadone per year. There are few enduring clinical 
benefits from methadone detoxification and thus very low cost-effectiveness or cost-offset from this 
short term treatment.” (ASAM 2013, Report III by Chalk et al., p.66)  
Methadone maintenance is not a covered benefit under Medicare, and in some states it is not a covered 
benefit under Medicaid. As of May 2013, 31 state Medicaid fee-for-service programs were found to 
cover methadone maintenance treatment provided in outpatient narcotic treatment programs. Some of 
these states provide additional public funding through the SAPT block grant/ state funds for OTP's; 
and in 3 other states, methadone treatment is funded only through SAPT and/or state or county 
funds. In 17 states, there is no Medicaid fee-for-service funding of methadone maintenance treatment 
in their state programs. (See tables specifying which state Medicaid programs cover MMT and which do 
not, in ASAM 2013, Report I, by Rinaldo & Rinaldo.) In many states, MMT is more available than 
buprenorphine maintenance treatment (BMT) for uninsured and Medicaid patients. Working patients 
with private insurance may have access to buprenorphine but not to methadone. Access varies from 
community to community and significantly depends on health insurance coverage. Methadone clinics 
often have a sliding fee schedule; but if clients can't pay fees for MMT, they receive detox only. 
Beginning treatment:  Induction is conducted within OTP’s. Methadone is typically dispensed on site 
in oral form (with take home privileges for certain stabilized patients), rather than prescribed at these 
specialized clinics. (ASAM 2013, Report III by Chalk et al.)  
Dosage:  varies from about 30 mg/day to over 100 mg/day, depending upon genetic and opioid use 
histories of particular patients (ASAM 2013, Report III by Chalk et al.). 
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Factors Favoring Office-Based Maintenance Treatment with Naltrexone: 
Naltrexone is an FDA approved alternative to opioid agonist treatment for patients with opioid 
dependence. A long acting opioid antagonist available in both oral and injectable formulations, it does 
not produce euphoria and is not addicting. Medication compliance and retention rates with naltrexone 
treatment are low, however, limiting its clinical effectiveness. Patients may continue to experience 
cravings and may not be motivated to maintain adherence to the medication regimen. (ASAM 2013 – 
Report III) Recent studies of opioid-dependent adults have found that “oral naltrexone, with or 
without psychotherapy, was no better than placebo or no pharmacological treatments with regard to 
retention in treatment, use of the primary substance of abuse, or side effects (Minozzi 2011); and that 
extended-release injectable naltrexone (XR-NTX) had poor to modest retention rates which improved 
with employer-enforced incentives contingent on treatment (Everly 2011, DeFulio 2012). No specific 
studies involving people who are homeless are available. Naltrexone is likely to be most useful for 
patients who are highly motivated to achieve abstinence (employed, younger/ having used drugs for only 
a short time, under threat of legal sanctions) and when a family member or close friend is available to 
administer and manage the medication (WHO 2009, ASAM 2013).   
1. Support from significant other or family 
2. Abstinence mandated as condition of employment or under threat of legal sanction 
3. Contraindications to buprenorphine or methadone maintenance 
4. Patient preference and values   
Advantages of naltrexone maintenance therapy: 
 Clinical effectiveness in eliminating opioid use with adherence to prescribed medical regimen – 
extremely effective in blocking actions of self-administered opioids: 24–36 hours (oral); up to 30 
days (injectable) 
 Safely blocks the risk of overdose when taken 
 Can be stopped abruptly without withdrawal symptoms 
Disadvantages: 
 Unpopular with opioid-dependent patients (strong side effects, long pre-treatment withdrawal 
requirements) 
 Not compatible with the need for opioid analgesic therapy (blocks the effects of opioid analgesics) 
 May be intolerable for patients with severe opioid dependence 
 Risk of fatal complications  
 Poor adherence/retention rates for oral formulation except with mandatory treatment 
 High costs of injectable formulation 
 No evidence of enduring benefits when used only in detox regimens 
 Increases risk of overdose when treatment stops and tolerance is decreased 
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Elements of Planning for Maintenance Treatment with Extended-Release Injectable Naltrexone: 
Cost considerations: The average cost of a single monthly injection of extended-release naltrexone 
averages between $850 and $1,100 depending on insurance coverage; per monthly dose is approximately 
$700 (ASAM 2013 p.67) /$850 – $1,100 (AATOD 2011). In 2013, Medicaid coverage of injectable 
sustained release naltrexone (Vivitrol®) was known to be available in 42 states; nevertheless, utilization 
management requirements (prior authorization, quantity limits, step therapy) in some states limit access 
to this treatment modality. Depot naltrexone is covered by Medicare and by many commercial third 
party carriers. “There is no doubt about the clinical effectiveness of naltrexone in eliminating opioid 
use but very poor patient retention rates for the oral medication and high costs of the injectable 
medication compromise definitive economic conclusions about this medication at this time” (ASAM 
2013, Report III by Chalk et al., p. 176).  
Beginning treatment:  Patients with opioid dependence must be fully withdrawn from all opioids for 
up to 7–10 days before beginning naltrexone treatment. “Unfortunately, during this period, many 
patients relapse to use of opioids and are unable to start on naltrexone.” (VA/DoD 2009)  
Dosage:  Administered via intramuscular injection, extended-release naltrexone is effective for 30 days. 
There is no need to adjust dosage for weight, height, age, gender, or health status; a single injection of 
380 mg maintains blood levels above 1 ng/cc 4–5 weeks. (AATOD 2014) The minimum duration of 
naltrexone maintenance treatment is 6–12 months. Because naltrexone is an antagonist, it can be 
stopped abruptly without withdrawal symptoms; however, careful clinical evaluation of relapse risk is 
recommended prior to discontinuation. (Kleber 2007) 
Risks:  “Both oral and extended-release formulations of naltrexone have been associated with patient 
deaths due to accidental opioid overdoses while taking either of these medications. In many cases, 
overdosing may be due to the blocking effect of naltrexone, with relapsing patients taking large 
amounts of opioids to try to overcome the blockage. In addition, patients treated with extended-release 
naltrexone may have reduced tolerance to opioids and be unaware of their potential sensitivity to the 
same, or lower, doses that they used to take of opioids. For such patients who relapse after a period of 
abstinence, the dosages of opioids previously used may have life-threatening consequences, including 
respiratory arrest and circulatory collapse.” (ASAM 2013, Report III by Chalk et al.) “Patients with severe 
opioid dependence should be cautious taking naltrexone; also, naltrexone is not recommended for 
people with cirrhosis who have a Child’s severity rating of C or above.” (WHO 2009, p. 46) For these 
reasons, medication-assisted treatment with naltrexone may not be appropriate for homeless patients with opioid 
dependence whose severity level and comorbidities could place them at risk for adverse consequences. 
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Pros and Cons of Maintenance Medications for Treatment of Opioid Dependence 
 
 
METHADONE BUPRENORPHINE/ NALOXONE NALTREXONE 
Pros 
 Effective in engaging and retaining 
patients;  
 Reduces withdrawal and craving 
symptoms 
 Reduces opioid but not non-
opioid abuse 
 Reduces risk of infectious 
diseases 
 Highly structured - ability to 
establish daily routine for taking 
medication 
 Strong connection to counseling 
 Decreased worry about 
loss/diversion of medication 
 Similar efficacy to that of 
methadone 
 Overdose risks are far lower than 
for methadone 
 Far more accessible than 
methadone - available from 
specially trained primary and 
generalist physicians 





 Extremely effective in blocking 
actions of self-administered 
opioids: 24-36 hours (oral); up 
to 30 days (injectable) 
 Safely blocks risk of overdose 
when taken 
 Can be stopped abruptly 
without withdrawal symptoms 
 Most useful to highly motivated 
patients likely to achieve 
abstinence (e.g., healthcare 
professionals) 
Cons 
 Limited availability 
 Many patients unable to tolerate 
highly structured environment 
 Sedating and anxiolytic opioid 
effects (pro for some patients) 
 Does not change craving for 
other drugs  
 No evidence of enduring benefits 
when used only in detox 
regimens 
 Initial induction requires 
abstinence to avoid precipitated 
withdrawal 
 Increasing evidence of lethal 
intranasal/ injection abuse 
 Fatal overdoses can occur if 
combined with other sedatives 
(benzodiazepines, alcohol).  
 No evidence of enduring benefits 
when used only in detox regimens 
 Unpopular with patients (strong 
side effects, long pre-treatment 
withdrawal requirements) 
 Risk of fatal complications  
 Poor adherence rates for oral 
formulation except with 
mandatory treatment. 
 High cost of injectable 
formulation 
 Blocks effects of opioid 
analgesics 
 Increases risk of overdose when 
treatment stops and tolerance is 
decreased 
 No evidence of enduring 
benefits when used only in 
detox regimens 
 Least useful for homeless 
patients  
Sources:  American Society of Addiction Medicine. (2013). The Effectiveness of Pharmacotherapies for the Treatment of  
Opioid Disorders: A Systematic Review; World Health Organization (2009). Guidelines for the Psychosocially Assisted  
Pharmacological Treatment of Opioid Dependence 
 
"Any of these potent, safe medications [methadone, buprenorphine, and naltrexone] can provide 
 important assistance in reducing opioid use among addicted patients. However, it is equally clear 
 that most opioid addicted patients concurrently suffer from related physical and mental problems,  
deteriorated personal and social relationships and often inability to self-support a productive lifestyle.  
The role of counseling, social services, monitoring with consequences and peer supports can provide  
much of what these potent medications cannot provide. But these medications can also offer 
pharmacological assistance in stabilizing signs and symptoms that so often lead to patient termination  
from so-called abstinence-oriented treatments. It is simply efficient and prudent to combine the best 
of recovery-oriented social services with these medications to offer patients the best chance of a 
full recovery."  — American Society of Addiction Medicine (ASAM 2013), pp. 24–25 
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Non-Medication-Assisted Treatment for Opioid Use Disorders 
 
Non-medication-assisted treatments can play a critical role on the road to recovery,  even for 
patients receiving opioid agonist treatment. Engaging people in recovery activities; helping them 
find sober environments, education/ training opportunities, and harm reduction therapy; teaching 
stress management and distress tolerance skills; recognizing and providing treatment for 
comorbidities including PTSD, TBI, and other substance abuse — these and other non-
pharmacologic interventions often make the difference between treatment failure and continued 
progress toward recovery despite periodic setbacks. 
 
 Harm Reduction Therapy  Harm reduction is a set of practical strategies and ideas aimed at 
reducing negative consequences associated with drug use. This approach can be beneficial 
regardless of treatment modality. It is particularly supportive to and respectful of people 
experiencing homelessness, who regularly interact with systems and situations that limit self-
determination and lack respect. Harm reduction therapy relies on collaboration, respect, and stage-
based interventions, and acknowledges self-defined, positive change. Therapists focus on client-
defined priorities and acknowledge that any improvement that reduces harm is beneficial, whether 
or not substance use is continued. 
Recommendations: 
1. Set the stage for honest communication to foster the therapeutic relationship.  View everything 
you do as treatment, from the briefest hello to an ongoing therapy relationship. View all interactions as 
in the service of building and maintaining the therapeutic relationship, knowing that 
relationship is the key to all behavioral change. Provide space and time for client and therapist 
to “move toward” each other (share perspectives, build mutual trust, collaborate on strategies to 
address expressed concerns), based on client readiness to engage at each step of this process.  
2. Avoid punitive sanctions for drug use  Policies regarding opiate or other drug use during treatment 
should be as permissive as possible given safety (overdose) concerns. Refusing or significantly restricting 
services in response to illicit drug or alcohol use will only increase chances that clients will try to 
deceive providers and engage in other behaviors that are interpreted as “drug seeking.” More 
frequent contact, honest exchange of conflicts, and adjusted dosing schedules should be the 
primary interventions. Consider use of a treatment contract/ patient-provider agreement that 
specifies expectations of the client and the therapist/ treatment provider to promote mutual 
accountability. Such agreements should change over time in response to changes in the plan of 
care and in the client’s function and behavior. (Wismer 2011)  
3. Flexible dosing schedules/locations, etc.  Recognize that flexibility is key to beginning a 
therapeutic relationship. Services should offer drop-in or sidewalk sessions, drop-in support groups, 
regular therapy appointments, and psychiatric medications. This means meeting and engaging 
individuals on the street, in the waiting room, or outside a bathroom door to begin the process of 
developing a trusting relationship in which people can, over time, bring themselves to the 
therapeutic encounter and begin to see that relationship as a resource rather than as an intrusion.  
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4. Flexible dosing schedules/locations, etc.  Recognize that flexibility is key to beginning a 
therapeutic relationship. Services should offer drop-in or sidewalk sessions, drop-in support groups, 
regular therapy appointments, and psychiatric medications. This means meeting and engaging 
individuals on the street, in the waiting room, or outside a bathroom door to begin the process 
of developing a trusting relationship in which people can, over time, bring themselves to the 
therapeutic encounter and begin to see that relationship as a resource rather than as an 
intrusion. Keep the door open for individuals who aren’t ready to ask for help. For opioid-
dependent individuals seeking help for co-occurring conditions, adapt your practice to provide 
easy access to appropriate treatment modalities consistent with their values and preferences. 
Because medications have harmful side effects, however, dosing should always be contingent on 
demonstrable, functional benefits to the patient. If the patient is not benefiting from a 
medication, it should not be prescribed.   
5. Chronic stress must also be treated.  Inability to tolerate painful emotions can often lead to opioid 
dependence and relapse. Lifestyle issues, psychiatric issues, and stress associated with homelessness 
are alleviated by opioids. Addiction treatment programs should provide clients with 
opportunities for respite, relaxation, and fun.  
6. Use appropriate medications to treat underlying depression and anxiety.  Avoid prescribing 
benzodiazepines for patients receiving medication-assisted treatment for opioid use disorders.  When taken 
in combination with opioid agonists/partial agonists (methadone/ buprenorphine), 
benzodiazepines are associated with possible long-term worsening of depression and anxiety 
disorders and can result in excessive sedation/lethal drug overdose. Be aware that methadone 
may increase the serotonergic side effects of SSRIs (Treatment Guidelines, Medical Letter, Jun 
2013; 11(130).)  
 
Key Elements of Harm Reduction Practice 
 Low threshold - Locate treatment activities in places where homeless individuals with substance use 
disorders congregate – e.g., street corners, community drop-in centers, needle exchanges, primary care 
clinics, soup kitchens, food pantries.  
 Integrated - Harm Reduction-informed treatment provides integrated care for drug problems, mental 
illness, and other psychosocial problems based on the client’s hierarchy of needs. Therapeutic approaches 
include motivational interviewing, cognitive-behavioral skills training, stress reduction, mindfulness, 
substance use management, life skills coaching, and nonverbal approaches such as drumming and somatic 
experiencing.   
 Trauma Informed - Program structures and therapist expectations must avoid replicating the 
characteristics of traumatic experiences, including coercion, intrusion, loss of control, powerlessness, loss 
of trust, and physical/ emotional attacks.  
 Respectful, collaborative therapeutic relationship - Prior experiences of treatment received by 
homeless people with addiction disorders may have been largely negative. Harm reduction therapy 
attempts to offset negative expectations by repeatedly expressing welcoming affect, making affirming 
statements, and offering a respectful and collaborative relationship.  
  
— Patt Denning, PhD and Jeannie Little, LCSW, Harm Reduction Therapy Center, San Francisco, California 
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7. Assess stage of change for all targeted behaviors, symptoms, etc.  Recognize that people may be 
ready to take action and adhere to different treatment recommendations at different times.  
8. Welcome people in crisis who present with difficult behaviors. Work with difficult behaviors 
rather than prohibiting them. Practice radical inclusion of all clients, including those with 
cognitive/mood/behavioral disorders that may cause them to be disruptive or very fearful and 
anxious in a clinical setting. Understand that behavior serves a purpose; despite sometimes self-
destructive aspects, it communicates essential information about a person’s history, feelings, and 
response to the present environment. Under the guise of creating “safety” for both clients and 
staff, programs frequently create rules and systems to prohibit “disruptive” behaviors.  Often this 
is more about staff comfort level than safety. At some point, most clients have crises. Train staff in 
nonviolent crisis intervention; educate them to distinguish dangerous behaviors from disruptive 
or inconvenient behaviors. Commit clients to an involuntary hold if absolutely necessary, but not 
often. Crisis prevention should be the priority; because emergency hospitalization is often 
traumatizing and may be inconsistent with therapeutic goals, devote extensive time to talking with 
and settling a client who is in crisis in order to avert a dangerous situation. 
Tips For Dealing With Disruptive/ Anxious Clients: 
   Try to understand why the person is angry or upset.  
     Use active listening and an empathic, non-judgmental approach to alleviate anxiety. 
   Try to prevent acting out behavior by being proactive.  
     Approach apparently anxious clients with respect.  
     Address problems immediately, before they escalate. 
    Remain calm and professional; don’t take acting out personally.  
     Don’t let your own behavior escalate.  
     Take a break; get help from others who have better rapport with the client. 
    In an escalating situation, isolate the difficult person.  
     Separation from others often allows clients to save face and calm down. 
    Respect personal space; watch your body language.  
     Remain 3-4 feet from the client — in front and slightly turned.  
     Avoid challenging gestures, stance and facial expressions. 
   Tone of voice is important; don’t sound harsh. Be respectful.  
     Don’t communicate stress or negative expectations through your manner. 
   Speak clearly, slowly and simply. Don’t use jargon or large words.  
    Avoid jokes and arguments about what the person is seeing, feeling or experiencing. 
   Set limits that are clear, simple, reasonable and enforceable.  
    Ask something the client is capable of doing. Emphasize the positive.  
    Be understanding of the need just to “vent.” 
   After an incident, sit down with staff and debrief.  
    Discuss what worked and what didn’t to be better prepared next time. 
   The teachable moment is when the client has calmed down.  
    Remind client how to avoid anxious situations in the future –  but not in the 
    middle of crisis. 
       — Eve Rubell, MPH, Homeless Health Care, Los Angeles, Oct 2000 Healing Hands 
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9. Take care of staff.  Consider the care of staff as a critical component of all programs.  Opportunities 
for individual and group supervision must be standardized, and other stress-reducing 
components added (continuing education, required vacations, communal lunches, etc.). Staff 
must embody flexibility and responsiveness to myriad crises and stories in any given day. Just as 
a harm reduction therapist prioritizes developing a therapeutic relationship, program 
supervisors should prioritize supporting staff as they focus their attention on the many 
participants in community-based programs. 
 Peer support  Peer-delivered social support services have become an integral part of behavioral 
health care. Peer supporters help individuals with mental and substance use disorders navigate 
complex service systems and advocate for underserved and vulnerable populations throughout the 
recovery process. Peer mentoring and peer-run mutual support groups are among the most 
successful examples of peer recovery support for individuals with opioid use disorders who are 
homeless. (HCH Clinicians’ Network, Fall 2013, HCH Clinicians’ Network, 2009 Jan) 
- Peer mentors/ peer support specialists are individuals with lived recovery experience who have 
been trained and certified to help their peers gain hope and achieve specific life and recovery 
goals. Actively engaged in their own recovery from mental health or substance use disorders, 
peer specialists may be volunteers or paid employees hired to provide peer support services to 
others. “Recovery and healing occur within the context of supportive relationships; peers excel at 
building effective relationships that facilitate recovery (HCH Clinicians’ Network, Fall 2013).” 
For example, the Recovery Mentor Program established by Central City Concern in Portland, 
Oregon, assigns a peer mentor to every client receiving addiction management services. Mentors 
check in with clients daily, making sure they maintain their commitment to a regimen of 
intensive outpatient medical, chemical dependency, and mental health treatment. A significant 
reduction in drug use and criminal activity was demonstrated among clients with addiction 
disorders receiving these services (Herinckx 2008, HCH Clinicians’ Network, 2009 Jan).  
- Peer support groups  According to formerly homeless consumer advocates, peer-run support 
groups are “the biggest contributing factor in helping clients avoid relapse.” Consider initiating a 
short-term intervention to work with clients individually and in peer-led groups. Structure sequential 
sessions to gradually increase client education and involvement of paraprofessionals. Short-term 
interventions can become ongoing, just as recovery is. Set up a phone list so group participants 
can talk with each other daily. If a member isn't doing well, peers can alert a clinic staff member 
or paraprofessional to reach out and provide assistance to that individual.  
12-Step programs, self-help groups, or mutual aid groups such as Narcotics Anonymous (NA) 
may provide positive peer interaction, social support, and opportunities/connections to help 
patients meet basic needs. Programs based on the AA/NA model of recovery are philosophically 
committed to abstinence. Some of these programs consider the use of medically-assisted 
treatment for opioid dependence as differing little from illicit drug use and are strongly critical 
of participants who are receiving treatment for addiction and/or comorbidities; others are more 
tolerant. (White 2011) Attitudes and practices of mutual support groups vary by community. 
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For more information about peer recovery support services, see CSAT 2009 and the Resource Kit of 
Practical Peer Support Resources prepared by the HCH Clinicians’ Network (2013).  
 Acupuncture has been successfully used by a number of Health Care for the Homeless programs as 
complementary and alternative therapy to control post-acute opioid withdrawal symptoms—it helps 
with anxiety and provides pain relief. People with severe opioid use disorder/ dependence 
experience acute sensitivity to pain when withdrawing from heroin use.  Acupuncture is a 
nonpharmacologic treatment modality that is particularly appropriate for homeless clients because 
of its low cost and portability as well as its effectiveness in treating the symptomatology of pain 
syndromes, substance abuse, and HIV (Johnstone et al., 1994). (For more information, visit the 
National Acupuncture Detoxification Association website.)  
 Supportive housing with employment assistance Supported employment—particularly in 
combination with permanent supportive housing—has been demonstrated to be an effective model 
for individuals with a primary substance abuse diagnosis who experience homelessness. 
Employment as a treatment outcome assists in social reintegration, helps prevent relapse, and 
promotes economic self sufficiency.  
Central City Concern (CCC) provides a comprehensive recovery oriented system of care—including 
addiction treatment, supportive housing, and supported employment services—to homeless and low-
income individuals in Portland, OR, many of whom have addiction disorders (including opioid use 
disorders) with co-occurring mental and physical health problems and histories of criminal justice 
system involvement (Kraybill & Zerger 2003, HCH Clinicians’ Network 2009). Since 1992, CCC 
has operated employment assistance programs that focus on the needs of chronically homeless 
adults, veterans, and formerly incarcerated individuals. A review of program outcomes, 2007–2009, 
found that 71% of all clients served by these programs achieved employment; clients who 
transitioned into permanent housing were employed at the highest rate (85%). (Herinckx 2010) 
 
“In formulating policies and practices related to patient referrals to recovery mutual aid groups, 
medication-assisted treatment programs will need to consider the effects of full versus restricted 
participation on recovery outcomes. ... Many patients in medication-assisted treatment are greatly 
benefiting from NA, and ...there are NA members who were able to taper successfully from 
medications with the support of NA. (No study has been conducted of the experiences of these 
latter NA members.) But comments [from members] also raise the question of potential harm that 
might occur to patients from the attitudes they encounter towards medications within NA—either 
through the consequences of precipitously terminating their medication use or through being denied 
the benefits of key ingredients of the NA program.”  (White 2011) 
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ASSOCIATED PROBLEMS, COMPLICATIONS  
 
Problems & Complications Related to Treatment for Opioid Use Disorder 
 Drug overdose  As already discussed, opioid-dependent people experiencing homelessness are at 
disproportionately high risk of lethal drug overdose. Fatal overdose is less likely with 
buprenorphine than with use of illicit opioids or other medications prescribed for analgesia. Be 
mindful of the use of medications and drugs of abuse that may cause CNS depression in the abstinent patient 
if used in combination with opioids. Although these medicines can play an important role in therapy 
for patients with opioid use disorders, providers should monitor these patients closely and explain 
the risks.  (See pp. 24 –26 for a detailed discussion of opioid safety and overdose prevention and 
response education.)  
 Adverse drug-drug interactions  Consider designating one clinician with expertise in treatment of 
severe substance use disorders to approve and monitor all prescribed medications and drug monitoring 
analyses, in order to prevent lethal or non-therapeutic medication combinations. List all current 
medications, the monitoring physician, and the chemical dependence diagnosis on the front page 
of medical records to reduce risk of prescribing medications that will trigger relapse when patients 
with severe substance use disorders present to the emergency room or are seen during clinic visits. 
Sharing information with pharmacists about a patient’s opioid use and any medically-assisted 
treatment received can also facilitate monitoring of potential drug interactions; but written patient 
Major Recommendations: 
 Carefully assess for comorbidities that can complicate or interfere with treatment of opioid use 
disorders. Manage co-occurring conditions simultaneously. 
 Provide opioid safety education on the effects of opioids including the possibility of overdose to all 
patients with a history of substance use and to patients taking opioid medications for pain 
management.  
 Institute regular monitoring of all prescribed medications taken by the patient to prevent prescription 
of lethal or nontherapeutic medication combinations, and to reduce risk of prescribing medications 
that will trigger relapse in patients with substance use disorders. 
 If diversion/ misuse of opioid agonists is suspected, explore patient motivations; re-evaluate the plan of 
care; implement strategies to minimize risk of diversion/ misuse (random drug tests, alternate day 
dosing, prescription monitoring program, directly observed therapy). Balance overall benefits of 
continuing MAT with potential harms. 
Rationale: Mortality risks are significantly increased by missed diagnoses of serious medical conditions associated with 
opioid dependence, and by drug overdoses precipitated by reduced tolerance following a recent period of abstinence or 
use of drugs/ medications that cause CNS depression if combined with opioids. Diversion of opioid agonist medications 
used therapeutically to prevent withdrawal symptoms is common among people unable to access addiction treatment. 
Clinicians working with homeless patients should be cognizant of the high rates of addiction, mental illness, and extreme 
poverty in this population. Lack of financial resources, limited access to treatment, and barriers to affordable housing 
(being screened out as potentially "high risk" tenants due to chemical or mental health problems and/or criminal record) 
are primary reasons why people with opioid dependence experience homelessness. 
Evidence: Recommendations are based on expert consensus of practitioners experienced in homeless health care with 
expertise in primary care, addiction medicine, psychiatry, harm reduction therapy, and overdose prevention.  
Sources:  Alford 2007, Alford 2011, Doe-Simkins 2013, Hwang  2008, Yokell 2011 
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consent/ signed releases would be required for such disclosures, consistent with privacy protections 
afforded to alcohol and drug abuse patient records by 42 Code of Federal Regulations (“CFR”) Part 
2. (For more information, see SAMHSA's Frequently Asked Questions: Applying the Substance 
Abuse Confidentiality Regulations to Health Information Exchange.)  
Before MAT is initiated, warn patients about severe side effects and risk of lethal overdose from combining 
heroin with other opiates, methadone, alcohol, or other drugs that potentiate overdose. Medications that may 
interact with common drugs of abuse are specified in Appendix D, prepared by pharmacists at 
Outside In, a homeless health care program in Portland, Oregon. (The pharmacodynamic 
interactions listed for heroin would also apply to prescription opioids.) For more information about 
drug-drug interactions, see Indiana University's cytochrome -450 drug interaction table. Be aware of 
potential interactions between some antiretroviral medications and opioid agonists that may diminish the 
effectiveness of treatment: 
Potential Interactions between Antiretrovirals and Opioid Agonists 
Drug Potential Interaction  Recommendation 
ritonavir, atazanavir 
(protease inhibitors) 




At higher doses, may decrease concentration of 
methadone 
Monitor for symptoms of opioid withdrawal 
and adjust methadone dose if necessary. 
efavirenz,  nevirapine 
(NNRTIs) 
May decrease concentration of methadone 
Monitor for symptoms of opioid withdrawal 
and adjust methadone dose if necessary. 
efavirenz 
 
May decrease concentration of buprenorphine 
Monitor for symptoms of opioid withdrawal 
and adjust buprenorphine dose if necessary. 
buprenorphine May make tipranavir/r (NNRTI) less effective Co-administer the combination with caution. 
  Sources:  Foisy & Tseng 2013, Antoniou & Tseng 2012 
 Diversion/ misuse of prescribed medications  Buprenorphine/naloxone obtained on the street or 
from others with a prescription is commonly used to prevent withdrawal or control withdrawal 
symptoms rather than to get high (Alford 2011). This can be more an indicator of lack of treatment 
access than of substance abuse per se. Buprenorphine/naloxone is generally ranked as the least-
abused or misused opioid in the U.S., with lower rates of abuse than heroin, oxycodone, 
hydrocodone, methadone, morphine, or fentanyl. In some instances, patient misuse of 
buprenorphine by injection or inhalation may be indicative of sub-optimal clinical dosing. One 
study found that three quarters of injection drug users and half of non-IDUs used diverted 
buprenorphine because they could not afford to enter formal drug treatment. If diversion is 
suspected, balance overall benefits of continuing treatment with potential harms. (Yokell 2011)                                
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Strategies to minimize diversion/ misuse of buprenorphine:  
 Use random urine drug tests to assess for diversion or misuse (e.g., whether the patient is taking 
some of the medication but is not adhering to the prescribed regimen). 
 Consider use of alternate day dosing with sublingual buprenorphine to decrease diversion.  
 Consult prescription monitoring programs to verify medication dosing and a history 
of controlled substances dispensed to individuals under your care.  Most states now have or plan 
to have a prescription drug monitoring system (see http://pmpalliance.org/).  
 Consider use of directly observed therapy to ensure compliance with BMT – a strategy that has 
been successful in promoting adherence to antiretroviral therapy for HIV infection.  
 Decrease demand for illicit buprenorphine by increasing the availability of buprenorphine and 
buprenorphine/naloxone. 
 
(See pp. 55–56 for more guidance on prevention of diversion/ misuse.) 
 
Problems & Complications Related to Other Factors: 
 
 Missed diagnoses  Carefully assess for comorbidities that can complicate or interfere with treatment of opioid 
use disorders. The diagnosis of opioid use disorder is generally straightforward. The occurrence of co-
existing conditions, however, may be missed due to the overwhelming burden of living with 
physical dependence to an opioid and the daily struggle to obtain opioids to avoid withdrawal. 
Comorbidities common to homeless populations—including psychiatric illness, HIV infection, 
hepatitis C, and chronic substance use disorders—correlate with unsuccessful treatment of severe 
opioid use disorder/ dependence (Alford 2007). Management of concomitant addictions (especially 
to benzodiazepines) and other psychiatric comorbidities is important, whether an individual is 
receiving medication-assisted treatment of opioid use disorder or not. Use multidisciplinary clinical 
teams to provide integrated primary and behavioral health care, including simultaneous treatment of co-
occurring substance use, mental health disorders and infections associated with intravenous drug use. 
Because the common presentation of polysubstance use disorders often complicates the treatment 
of opioid dependence, this aspect of the diagnosis must not be missed. For example, comorbid 
alcoholism and benzodiazepine use disorder can interfere with MAT with buprenorphine, making 
it more dangerous. The occurrence of severe medical conditions resulting from opioid use disorders 
can be mistaken for withdrawal or self-neglect; therefore careful assessment for acute and chronic 
infections and other co-occurring conditions is extremely important.  
"Discussions of diversion should be broadened beyond the risks or legal implications 
associated with this activity. Strong consideration should also be given to the medical, social, 
public health, and economic benefits that arise when opioid-dependent individuals use 
buprenorphine in a therapeutic manner to self-treat addiction and withdrawal symptoms or as 
a harm reduction approach to manage the risks associated with drug dependence. Any 
consideration of diversion should balance the overall benefits—both those seen in clinical 
patients as well as those seen in illicit users—with the potential harms." (Yokell 2011) 
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For individuals seeking treatment for opioid use disorders, follow up and treat co-occurring 
conditions at subsequent visits. For individuals who deny substance abuse but are actively using 
addictive substances, treatment of comorbidities can be a way to reduce harm and engage them in 
ongoing care. The National Quality Forum has developed a Multiple Chronic Conditions (MCC) 
Measurement Framework that articulates a shared vision for effectively measuring the quality of 
care provided to individuals with chronic, co-occurring health problems. Providers dealing with the 
complex spectrum of comorbidities associated with opioid use disorders in homeless populations 
might benefit from this approach.  
 Psychiatric disorders  Mental health problems such as depression, anxiety, and PTSD should be 
addressed simultaneously with opioid use disorder. Uncontrolled psychosis/mania or suicidal 
depression should lead to a psychiatric referral. Recognize that exacerbation of mental illness and 
erosion of coping capacity may result from cessation of buprenorphine treatment.  
Critical issues for homeless patients:  
1. Can the patient follow directions and understand risks and benefits of various treatment options?  
2. Is there a safe place to store medications for the patient, provider, or visiting nurse?  
3. Is the patient suicidal?  
4. Given the high prevalence of trauma in homeless populations, does the patient have a safe 
environment in which to begin the recovery process? 
 Injection-related infections and bloodborne disease Patients who are injecting substances should 
be counseled on proper injection techniques and given referrals to syringe exchange programs or 
supplied with sterile injection equipment. Injectors are at high risk for infections like endocarditis, 
cellulitis, necrotizing fasciitis, and abscesses along with vein damage and the transmission of HIV 
and viral hepatitis through the sharing of equipment.   
 Cognitive impairment  Memory deficits, impulse control, and low intellectual functioning  may 
interfere with treatment adherence. As many as 80% of homeless persons receiving 
neuropsychological testing have marked deficits in cognitive functioning (Highley, 2008). Cognitive 
impairments seen in homeless patients are often associated with traumatic brain injury (TBI), mental 
illness, chronic substance abuse, infection, strokes, tumors, poisoning, or developmental disabilities. 
Many of these patients were victims of assault during childhood prior to becoming homeless. 
Homeless people experience high rates of head injury (Carlson 2008). A study in Toronto found a 
lifetime prevalence of TBI in 53% of a representative sample of 904 homeless adults, with 
significantly increased likelihood of seizures, mental health problems, drug problems, and poorer 
physical and mental health status (Hwang 2008). More structured treatment settings or directly 
observed therapy may be preferable for these patients, whose cognitive impairments may be confused 
with treatment resistance/noncompliance. 
 Acute and chronic pain  Homeless populations suffer disproportionately from health problems 
associated with acute and chronic pain (trauma, peripheral vascular disease, viral hepatitis, 
HIV/AIDS, psychiatric illness, substance use disorders) that is exacerbated by limited access to 
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treatment (Wismer 2011).  A history of chronic pain can complicate diagnosis of opioid use 
disorder. Many experts would favor using buprenorphine or methadone alone in divided doses for 
analgesia. Other opioid analgesics can be used with methadone and rarely with buprenorphine for 
individuals with severe opioid use disorders and pain. (For a discussion of clinical options for 
treating acute pain in patients receiving opioid agonist therapy, see Alford 2006.)   
 Discrimination  Consider the potential for methadone and, to a lesser extent, buprenorphine 
recipients to be discriminated against by employers requiring routine drug tests. Methadone may 
show up on employee drug screens; buprenorphine is unlikely to show up on routine drug screens. 
As noted, some self-help groups discriminate against participants receiving medication-assisted 
treatment for opioid dependence because it is mistakenly seen as equivalent to active drug use and 
therefore contrary to abstinence-only as a preferred recovery strategy. Employers, housing providers, 
and many health care providers continue to need to be educated that methadone and buprenorphine 
used for treatment do not constitute active substance abuse, and in fact are likely to result in individuals’ 
being much more stable. It may be helpful to be proactive in providing patients with a letter 
describing the medicine they are taking “for a chronic condition” under your care.  
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FOLLOW-UP   
 
Major Recommendations: 
 Determine frequency of follow-up based on stability of the patient and his/her living situation and risk 
of diversion/ misuse/ abuse of medications used for treatment of opioid use disorders or other 
substances.  
 At each visit, assess for behaviors outside the treatment plan, including a psychosocial assessment. 
Consider causes related to homelessness — missed appointments due to competing priorities or 
unexpected events (e.g., in jail, delayed by another appointment), stolen medications (e.g., assault, 
theft in shelter). 
 Provide medical respite care facilities where patients can convalesce when ill, recuperate following 
hospitalization, or receive end of life care. Facilitate entry into permanent housing with supportive 
services on site or in the community, to alleviate many associated problems and complications. 
Rationale: Homeless people’s lives are unstable, and they have a higher prevalence of mental health and substance use  
problems compared to the general population. Medications prescribed for homeless patients are more often stolen, 
overused, traded and/or sold. Most aspects of addiction treatment are more difficult without stable housing. Substance 
use declines when people become housed. 
Evidence:  Recommendations are based on expert consensus of practitioners experienced in homeless health care 
with expertise in primary care, addiction medicine., psychiatry, harm reduction therapy, and overdose prevention.  
Sources: Aidala, 2005, Edgington 2011, Post 2008, Wismer 2011 
 
 Frequency of follow-up for patients receiving office-based treatment for opioid use disorder  
Determine frequency of follow-up care based on stability of the patient and his/ her living situation, and risk of 
diversion, misuse, or abuse of medications used for treatment of opioid use disorders or other substances. 
Recommended follow-up can be daily or weekly until the patient is stabilized (i.e., until the dose 
has been stable and urine drug screens have been clear of other opioids for a few weeks). For 
patients with polysubstance use disorders, more frequent visits with random urine/blood drug 
screens may be necessary. Drug testing should be targeted at specific goals; seek guidance on lab 
interpretations and plan what to do with test results. Therapeutic use of point of care or in-office 
urine drug testing can be extremely helpful for homeless patients with whom follow-up by phone is 
difficult. Ask patients what drugs they expect would show up on a drug screen; many patients will 
tell the provider what drugs they have been using in response to nonjudgmental questioning.  
If the patient is not free of non-prescribed opioids, if other drugs or non-prescribed/contraindicated medications 
show up on drug screens (alcohol, benzodiazepines, repeated evidence of cocaine or marijuana), or if there is no 
buprenorphine in the urine (which could be a sign of diversion), re-evaluate the plan of care to determine the 
safest and most effective strategy for continuing medication-assisted treatment for opioid dependence. A special 
test is needed to detect buprenorphine. Many in-office urine tests only detect non-synthetic opioids 
such as morphine (to which heroin is metabolized) and codeine. Urine testing for the presence of 
buprenorphine may not be readily available or may be too expensive for many programs to 
implement. Benzodiazepines are hard to detect in urine screens because most tests only look for 
one or two metabolic products.  
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Between-visit pill counts can be helpful for patients who have transportation to the clinic, which 
can also be conducted at outreach sites. If the patient needs more medical and psychosocial support 
than can be provided in your health center, consider other treatment alternatives/settings (detox 
center, inpatient care, intensive outpatient treatment program, supported housing) and make 
appropriate referrals.   
If prescribing an opioid agonist, make sure that follow-up occurs before the prescribed medication 
runs out. Coordinating prescription refills with medical appointments helps encourage patients to 
come to the clinic for follow-up of comorbid medical conditions.  
 Medication refills  In general, prescriptions should be of shorter duration to help reduce misuse/ diversion, 
overdose, or loss of medications. Depending on the patient’s needs, one can gradually increase the 
frequency of prescriptions from daily, to every 3–5 days, to bi-weekly. Extend or decrease prescription 
duration consistent with appropriate use of the medications and patient ability to store them securely. 
Designate an authorized physician to refill opioid and other medications if the prescriber is 
unavailable to do so. The clinician’s responsibility to the patient lies in providing the medications on 
an agreed-upon basis.  
 
 Progress review  At every visit, review progress toward completion of the diagnostic work up, behavioral 
interventions, medication adherence, receipt of/ adherence to other treatments, and progress toward patient 
goals. Assess the patient’s response to treatment (each visit), functional improvement (each visit), 
and mental health and substance use (at regular intervals, depending on original assessment 
results). Assess medication side effects. Change medications/ treatments/ treatment goals as 
needed. Keep expectations clear. 
 
 Medication storage evaluation Medications prescribed for homeless patients are frequently stolen, 
overused, shared, traded, or sold. Medications may be lost as people travel from place to place, or 
confiscated by police if arrested/ questioned for loitering (sitting on a bench or on the ground), 
trespassing (camping somewhere), and/or addressing other basic human needs. Follow-up should 
include a re-evaluation of the patient’s ability to manage a certain quantity of medications and strategies to 
keep medications safe. 
 
 Medical respite care/ permanent housing  Research has shown that substance use declines when 
people become stably housed (Aidala, 2005). Housing should be a component of any treatment strategy to 
manage opioid use disorder. Provide or refer to medical respite care facilities where homeless patients 
can convalesce when ill, recuperate following hospitalization, and receive harm reduction informed 
addiction treatment (Ciambrone & Edgington, 2009, Edgington 2011). Facilitate entry into 
affordable permanent housing with supportive services in the community and/or available on site—an 
integrated package of care management with coordinated primary and behavioral health care—to 
reduce problems and complications associated with treatment (Post 2008).  
 Case management  Assess the patient's need for social work/ case management/ legal services at every visit. 
(“Has anything changed? Lost Medicaid? Problems in living situation? ER visit? Family problems?”)  
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Model of Care 
 
SERVICE DELIVERY DESIGN 
Major Recommendations: 
 Design service delivery systems based on meeting patient needs, promoting consistency in practice, 
and supporting staff that work with challenging patients.   
 Consider use of unconventional treatment sites (e.g., mobile methadone vans), addiction counseling 
on a drop-in basis, flexible treatment goals and desired outcomes, and creative strategies for 
recruiting patients into treatment.  
 Establish collaborative relationships with methadone maintenance providers, detoxification programs, 
and other inpatient and outpatient addiction treatment programs for cross referral and coordinated care. 
 Integrate primary and behavioral health care and use a harm reduction approach to the management of 
opioid use disorders. Use multidisciplinary clinical teams working at the same location. Locate treatment 
activities in places where homeless individuals with substance use disorders congregate. Provide 
recovery-oriented support services (e.g., peer mentoring, group therapy, employment assistance). 
Rationale: It is important to develop a system of care that supports the patient-provider relationship, given the 
barriers that homeless patients face in obtaining treatment for opioid use disorder and the challenges that providers face 
in providing an appropriate combination of treatments in a safe and effective manner.  Also important is developing a 
system of care that addresses the myriad needs of many homeless patients (e.g., medical, behavioral health, and social 
services) in a coordinated way.  
Evidence: Recommendations are based on expert consensus of practitioners experienced in homeless health care with 
expertise in primary care, addiction medicine, psychiatry, and harm reduction therapy.  
Sources: Alford 2011, Altice 1999, Denning & Little 2011, Goyer 2011, Meinbresse 2013, SAMHSA 2013 (TIP 55).  
 
 Goals of optimal service delivery Design service delivery systems based on meeting patient needs, promoting 
consistency in practice, and supporting staff that work with challenging patients. Recognize that people with 
opioid use disorders who are experiencing homelessness need a broad array of services and 
resources to meet basic needs, maintain/ improve health, and mitigate conditions inherent to 
homelessness that limit health care access and complicate treatment adherence: 
1.  Decent, safe, and affordable housing with supportive services, on site or in the community;  
2.  A livable income/ resources – to pay for food, clothing, shelter, and health care; and to meet 
requirements of the correctional system (e.g., for regular drug testing);  
3.  Access to overdose prevention supplies, syringes, and education on reducing drug-related harm;  
4.  Access to comprehensive health care, including inpatient and outpatient care, and ongoing 
aftercare through case management and/or peer mentoring;  
5.  An approach to care that takes into consideration the patient’s personal strengths, aspirations, 
and cultural/ religious/ spiritual preferences; 
6.  Monitoring and coordination of all medical prescriptions for every patient with a known 
substance use disorder, in emergency departments, clinics, and pharmacies; 
7.  Physical exercise and recreational activities; 
8.  Peer support/ community connections (group meetings, volunteer opportunities, advocacy 
activities to address the structural causes of homelessness);  
9.  Access to affordable transportation; and 
10.  Education and employment/ training opportunities. 
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 Service delivery adaptations recommended for patients experiencing homelessness:  
1.  Sites of treatment and other service delivery may be unconventional.   
Examples:  
 Mobile methadone vans in Seattle, San Francisco, Vermont, Omaha  
 San Francisco Drug Users Union – represents political interests and practical needs of 
chronic drug users (e.g., provides clean needles, harm reduction support group). 
 Harm Reduction Coalition, New York City – policy and advocacy for drug users; skills-
building training, community consultation and other technical assistance; overdose 
prevention education and advocacy; sponsoring and organizing regional and national 
conferences. 
2. Counseling may need to be on a drop-in basis or require more outreach to bring patients in. 
Examples: 
 Office-based opiate treatment (OBOT) experience in San Francisco 
 Individual and group counseling at Harm Reduction Therapy Center in San Francisco 
Tenderloin district 
3. Goals and desired outcomes of treatment may need to be flexible. 
Example: 
 As in other drug using populations, the only social connections and support that homeless 
patients have may be with drug-using friends or those with whom they share encampment. 
New social networks and support may need to be established for patients who are estranged 
from their families and from conventional social supports (e.g., the Recovery Mentor 
Program in Portland, Oregon). 
4. Recruitment into treatment may need to be creative and visible to people on the margins.  
Examples: 
 Heroin users encamped in alley adjacent to clinic with no effective outreach to get them into 
treatment 
 Success of project Homeless Connect model of having intake and health screening on site at 
large homeless services events 
 Special funding for treatment of homeless people may need to be developed. (This can be 
quite politically touchy and can elicit issues of discrimination, racism, etc.) 
 Many homeless women in need of treatment for opioid use disorders are connected to men 
also in need. Program flexibility is needed to accommodate treatment of couples. 
 Integrated services & collaborative care  Because of the high prevalence of co-occurring mental/ 
behavioral health conditions and other chronic illnesses in homeless populations, opioid-
dependent persons experiencing homelessness can greatly benefit from the integration of primary 
and behavioral health care with MAT. Integrated care exists when all staff work together 
collaboratively as a team, using the same clinical record in the same physical space with ongoing 
communication, and are rapidly accessible to intervene with patients when needed.  
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Examples: 
- Integrated primary/ HIV/ HCV care for patients in MMT or BMT:  Patients prioritize getting 
their daily methadone dose or office-based therapy with buprenorphine/naloxone, which makes 
these treatment settings ideal for integrated care — e.g., provision of primary care (flu shots and 
other immunizations),  HIV care, HCV care, etc., in the same location. (Altice 1999, Harris 
2010), Dilonardo 2011, HAB 2012) 
- Integration of primary and behavioral health care with MAT for opioid-dependent patients 
with co-occurring psychiatric disorders: Patients in BMT with active psychiatric diagnoses co-
managed with a psychiatrist. (Alford 2011) 
- Collaborative, coordinated care with nurse care managers can foster successful outcomes of 
BMT for opioid-dependent patients with complex psychosocial needs (Ibid.). 
Resources:  
 Integrated Care Quick Guide: Integrating Behavioral Health & Primary Care in the HCH 
Setting (Meinbresse 2013) 
 Key Elements of Integrated Care for Persons Experiencing Homelessness (Goyer 2011) 
 National Health Care for the Homeless Council's Webinar on Integrating Behavioral Health & 
Primary Care for People Experiencing Homelessness, February 19, 2013. 
 Recovery support services are especially important for homeless people with opioid use disorders. 
These may include peer mentoring, alcohol- and drug-free community (ADFC) housing, and peer-
to-peer support services.  
Recommendations for homeless patients: 
1. Provide peer-to-peer services in a modified program that doesn't necessarily require detox or 
treatment. This is a cost-effective strategy that can result in better outcomes due to increased 
client comfort level with peers compared to professional staff.  
Example: Central City Concern's Recovery Mentor Program in Portland, Oregon increases the 
number of successful outcomes for non medication-assisted treatment models and enables more 
opioid-dependent people to qualify for and maintain ADFC housing. 
2. Improve access to detox and opioid agonist treatment — especially for uninsured people and 
Medicaid recipients in jurisdictions where behavioral health services are limited. 
3. Promote comprehensive models of care that include both medication-assisted and non- 
medication-assisted treatment options.  
4. Foster access to decent, safe and affordable housing, including medical respite care, subsidized 
transitional housing, and permanent housing with supportive services. Housing is often the 
most stabilizing health intervention.  
 Advocacy  Involve both service providers and clients in policy advocacy to protect successful recovery models of 
care. Example: Oregon Health Authority's  Addictions and Mental Health Planning and Advisory 
Council  
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“Outreach and engagement is the process of coming alongside of someone who is struggling with homelessness and 
related health and social concerns, and sharing the journey in a way that leads to healing, wholeness and stability 
in community. Outreach and engagement activities can be seen as a movement through four phases of relationship: 
approach, companionship, partnership, and mutuality.”  — Craig Rennebohm, D.Min. (Kraybill 2005) 
 
 Outreach workers Recognize that social support is essential to successful treatment of opioid use 
disorders. Use outreach workers in the community to facilitate initial engagement with and provide support to 
people at risk for opioid overdose. Community health workers and case managers can facilitate 
treatment entry and retention of individuals who have not contemplated treatment before (Booth 
2004, Palepu 2011), stay in touch with clients by phone (if possible), meet with them in community 
shelters and transitional/permanent housing, and make sure they return for follow-up. Lack of 
engagement in treatment should not end outreach contacts; continue frequent contacts, which in 
themselves can be beneficial. 
 Outreach sites  Consider all client interactions, inside or outside the clinic, as outreach opportunities to 
engage people experiencing homelessness (Bonin 2010). Conduct outreach in locations where injection 
drug users are know to congregate – on the streets, in soup kitchens, shelters, transitional/ 
permanent supportive housing, and other places where homeless people receive services.   
 Group therapy  Provide ongoing opportunities for group therapy to patients with opioid use disorders.  
12-Step groups (based on the AA/NA model): Participants are likely to focus on abstinence 
support and goals and longer-term recovery issues.  
Major Recommendations: 
 Use outreach workers in the community to facilitate initial engagement with and provide support 
to people at risk for opioid overdose. Do outreach in partnership with a consumer/ peer 
counselor as much as possible. 
 Provide ongoing opportunities for group therapy to patients with opioid use disorder. 
 If possible, provide medication-assisted treatment where homeless people live (e.g., shelter-based 
treatment with buprenorphine). 
 Use a team approach in care planning and coordination to facilitate engagement.  
Rationale: Homeless patients often work with counselors, case managers, and/ or outreach workers who may 
explore opioid use issues when engaging the patient. These members of the care team often have more access to 
patients and are more accessible than medical providers. Caring for homeless patients is as much about building 
relationships as about clinical expertise. 
Evidence: Recommendations are based on expert consensus of practitioners experienced in homeless health care 
with expertise in primary care, addiction medicine, psychiatry, outreach/ case management, and harm reduction 
therapy.  
Sources: Bonin 2010, Booth 2004, Kraybill 2005, Palepu 2011  
 Health Care for the Homeless Clinicians’ Network  
ADAPTING YOUR PRACTICE: 
Recommendations for the Care of Homeless Patients with Opioid Use Disorders  
62 
Harm reduction groups:  Participants talk about the benefits of opiate replacement therapy, 
overdose risk, safer or reduced use of non-opiate drugs, and any non-drug related issues. (See pp. 
45–48 and Appendix A for detailed information about harm reduction therapy.) Convening groups 
several times a week  can provide an open forum for to discuss issues such as overdose risk. 
Encourage groups to continue discussions in shelter settings as well. (See pp. 48–49 for more 
information about peer support groups.) 
 Consumer involvement Do outreach in partnership with a consumer as much as possible. Use of formerly 
homeless clients to join staff in outreach efforts can foster rapport with clients by reaching out to 
friends and sharing their own experience with treatment and recovery. Consumers should be paid 
or provided stipends for their service and should be included as members of the care planning 
team. There is very well-organized methadone advocacy training and peer recovery support available 
from the Medicated Assisted Recovery Services (MARS) Project.  
 Shelter-based treatment  Provide buprenorphine maintenance treatment where patients live. People 
residing in homeless shelters who are actively using opioids are at high risk for overdose. To help 
reduce alarmingly high mortality rates from opioid toxicity, the Boston Health Care for the 
Homeless Program (BHCHP) pioneered office-based buprenorphine/naloxone (Suboxone®) 
treatment in a shelter setting—the first such program in the country. DEA regulations made it 
difficult to get approval from the Boston Department of Public Health to initiate shelter-based 
Suboxone treatment. Eventually, BHCHP succeeded in obtaining a waiver from the DPH to 
administer Suboxone in a shelter clinic, with strict adherence to DEA regulations. The homeless 
clinic now gets referrals from shelter staff, and BHCHP staff report that mortality rates secondary to 
opioid overdose have decreased among their clients. Work with medical boards and public health 
departments to obtain approval to administer buprenorphine (Suboxone) treatment in shelter 
settings consistent with DEA regulations. Be aware that it is essential to go through appropriate 
government channels in instituting treatment programs at unconventional sites to avoid losing 
prescribing authorization/medical licensure. 
OUTREACH STRATEGIES 
 Connect with people experiencing homelessness: Go with a person who is 
known in the area; utilize active/reflective listening; make eye contact; look for 
indications of drug use. Provide basic hygiene items, mittens, hats, backpack, 
information about where services are available. Keep coming back; trust is 
developed through consistency and respect. 
 Work with other agencies including harm reduction centers. Provide space 
for 12-Step and other peer support programs. 
 Dos & Don'ts: Wear casual clothing, not suits. Take cell phone for safety. Don't 
take calls, text, or use PDA/ computer while listening to people experiencing 
homelessness, who may already feel intimidated and ignored. 
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 Clinical team  Involve all members of the clinical team in care planning and coordination to facilitate 
engagement. Use outreach workers and case managers to promote initial engagement with the 
patient. The clinical team should include people who have experienced homelessness. Hire 
culturally competent staff who look and talk like the populations served or use an interpreter. 
(Bonin 2010) 
 
 Therapeutic relationship  Nonjudgmental and supportive patient interactions with members of the 
clinical team are essential for successful engagement in a therapeutic relationship. Recognize that 
caring for homeless patients is as much about building relationships as about clinical expertise.  Essential to 
building and maintaining trusting relationships with individuals who are homeless is person-
centered, trauma-informed, recovery-oriented care (Morrison 2007).6 Recognize that recovery is not a 
linear process, and that relapse is part of the cycle of behavioral change. (Bonin 2010) 
 Incentives Use incentives to promote engagement and treatment entry. (Bonin 2010, Booth 2004, 
SAMHSA 2013 TIP 55) 
Examples:  
1. Provide food and drink/ meal vouchers, hygiene products (toothbrush, toothpaste, soap, 
shampoo)/ clothing appropriate to the weather (socks, sneakers, hat, gloves).  
2. Providing condoms, safe sex literature, and safe drug use materials is a key step in engaging  
drug users in a conversation while meeting their basic needs. Syringes and other injection 
equipment, safer crack-smoking kits, condoms and other harm reduction supplies are highly 
desired by people who are using, and convey to the person that you are able to discuss drug use 
with them.  
3. Use foot baths to alleviate anxiety and increase comfort level. 
4. Hand out subway/bus cards or tokens to facilitate transportation to and from the clinic. 
5. Provide peer mentoring and linkage to housing opportunities and other resources. 
                                                 
6  Person-centered care emphasizes a partnership between care providers and recipients that encourages full participation of 
the patient, drawing on his/her strengths and inner resources, and promotes patient choice and self-determination. The 
care recipient determines the focus and pace of treatment, and defines outcomes based on his/her capacities and available 
supports.  
Trauma-informed care assumes that homelessness is a traumatic experience, which for many homeless people is 
compounded by serious medical and behavioral health problems and/or histories of abuse and neglect from which they 
still suffer.  
Recovery-oriented care fosters the process of recovery — healing and recuperation from illness or a medical procedure; 
restoration or retention of functioning; progress toward gaining or maintaining abstinence from the use of addictive 
substances; regaining a sense of safety, control, connection, and meaning following trauma; becoming stably housed and 
restoring one’s sense of purpose and a meaningful place in the community.  
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STANDARDS OF CARE    
Major Recommendations: 
 Adapt clinical practices to optimize care for patients who are homeless or at risk of becoming 
homeless considering the recommendations contained in this guide. 
 Offer medication-assisted treatment to any patient with an opioid use disorder.  
 Address acute and chronic medical problems related to drug use. 
 Offer naloxone to patients with an opioid use disorder and offer needle exchange to injecting drug   
   users, to the extent permitted by law and available resources. 
 Advocate for improved access for homeless and other underserved populations to a broader range of 
interventions for the management of opioid use disorders.  
Rationale: Employ the same standards of care for patients who are homeless as for those with more resources – based 
on scientific evidence, expert opinion, and recommendations of practitioners with extensive experience working with 
homeless people. Involving direct service providers and patients in advocacy adds credibility to the positions presented, 
helps counteract staff burn-out, and can facilitate the recovery process. 
Evidence: Recommendations are based on expert consensus of practitioners experienced in homeless health care with 
expertise in primary care, addiction medicine, psychiatry, and harm reduction therapy.  
Sources: FSMB 2013, Baggett 2013, Wismer 2011 
 Clinical standards  Employ the same standards of care for patients who are homeless as for other patients — 
based on scientific evidence, expert opinion, and recommendations of health care professionals. 
Adapt clinical practices to optimize care for patients who are homeless or at risk of becoming homeless, 
considering the recommendations contained in this guide.  
 Consumer involvement  Active involvement of patients in their own care is warranted as a basic 
principle of human rights — people should be involved in making decisions that affect their lives.  
 Prescription of controlled substances  DEA regulates the prescription of controlled substances. 
States differ in medical and pharmacy laws. Many states require second opinions, patient-provider 
agreements, urine drug tests, etc., of clinical practices that prescribe buprenorphine for treatment of 
severe opioid use disorder. Check with your state medical, nursing, and pharmacy boards; refer to 
the Model Policy for Use of Controlled Substances in the Treatment of Opioid Addiction in the 
medical office by the Federation of State Medical Board: Note: Treatment provided by office-based 
physicians is included in state prescription databases; however, due to federal substance abuse 
confidentiality laws (42 CFR Part 2), drugs prescribed at an OTP/NTP are not. 
 Licensure  Many states license acupuncturists, and those that do not may have rules or regulations. 
State certification requirements are available at: www.acupuncture.com/statelaws/statelaw.htm. To 
learn about training opportunities, consult the National Acupuncture Detoxification Association.  
 Advocacy  Integrate service with advocacy to improve access for homeless people to a broader range of 
interventions for the management of opioid use disorders and address the structural causes of homelessness. 
Advocacy is the educational process through which data, experiences, and insight are shared with 
those who craft public policy so that they may make informed decisions. Its aim is to educate 
policymakers about homelessness so that myths and stereotypes can give way to better-informed 
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decision-making and resource allocation. Involving direct service providers and recipients in 
advocacy adds credibility to the positions presented, helps counteract staff burn-out, and can 
facilitate patients’ recovery process. Encourage involvement in homeless advocacy groups at the 
national, state, and local levels. 
Consider advocating for: 
- Increased resources for provider licensure, licensing/approval of unconventional sites, and 
greater patient access to licensed prescribers for office-based treatment of opioid dependence. 
- Standardized Medicare and Medicaid coverage for medication-assisted treatment in every state. 
- Criminal justice diversion to treatment for opioid-dependent offenders and approval of 
treatment models that employ a Harm Reduction approach to care. 
- Progressive state medical and pharmacy laws/regulations that are more consistent nationally. 
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CASE STUDY: TREATMENT SELECTION FOR PATIENTS WITH OPIOID USE DISORDER 
History: Mr. K is a 30 y/o man who presents stating “I will die soon the way things are going.” He reports he has been using heroin 
for over 10 years and now injects in his jugular vein because his other veins are “trashed.” He has been told he has hepatitis C but 
does not know what stage. He was involved in a serious MVA 7 yrs ago with neck fracture requiring neurosurgery. He reports some 
neck stiffness and loss of range of motion. His family history is significant for “many functioning alcoholics.” At one time he was very 
successful as a heroin dealer but now he fears the violence on the streets is so severe that he is at risk of being killed. He lives with 
his girlfriend who also uses heroin and rents an SRO room when he can afford it. Otherwise he couch surfs or stays on the streets. 
He has tried methadone and states “it worked, it could have worked better but I wasn’t done, I was dealing heroin at the same time 
and using on top of it.” His usual dose was 70mg or less and this did prevent feelings of withdrawal and craving. He drinks “2-3 
beers per week” but usually only when he is waiting to get heroin and states alcohol “is never a problem.” He does not use other 
drugs. He recently had 7 mo clean living with a relative in a rural area but states “I always seem to want to mess up when things are 
going good.” 
Physical exam: Many old tracks and scars, Recent tracks in neck with some redness, Alert and oriented, Full PE deferred 
Patients stated goals: "I want to get my s--t together for real for real," take better care of self, take care of hep C, better diet - 
eat good foods, exercise, individual counseling, couples counseling, stop using heroin, get my own place, get a normal job 
Decisions for Mr. K: 
Would he benefit from treatment? 
Does he require Medication Assisted Treatment? 
Does he require “detox” or maintenance treatment? 
What are the possible benefits buprenorphine maintenance? 
What are the possible harms of buprenorphine maintenance? 
What are the possible benefits of methadone maintenance? 
What are the possible harms of methadone maintenance? 
What are the possible benefits of non medication assisted treatment? 
What are the possible harms of non-medication assisted treatment? 
What are the likely challenges to success? 
Does he have any contraindications to buprenorphine or methadone treatment? 
Can we treat him in an outpatient setting with limited resources? 
Can we treat him in a healthcare for the homeless setting? 
 
Treatment & Outcome: Mr. K and his girl friend were simultaneously started on Suboxone. They have both abstained from 
opioids for over 5 years. Mr. K struggles with anxiety and panic and binge drinks when these feelings are overwhelming. He has 
successfully apprenticed in a trade and is working. He is housed with his girl friend who became pregnant 18 mos after starting 
buprenorphine. She chose to continue Subutex throughout the pregnancy and she had a normal labor and delivery. Their son was 
discharged on hospital day #3 and is doing well.  
 
Barry Zevin, MD, Tom Waddell Health Center,  
San Francisco Department of Public Health, San Francisco, California (2013)  
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CASE STUDY: COUNTERING MYTHS ABOUT METHADONE MAINTENANCE TREATMENT 
 
A 50 year old man presents to the HCH drop-in urgent care clinic requesting a refill of blood pressure medication. He 
reports he has recently gotten out of prison and ran out of medication he had been prescribed. He gives a history of 
hypertension. He complains of a chronic cough that he attributes to smoking cigarettes. 
He is dressed in long sleeves and appears hesitant to take off his shirt to be examined. Overall he appears to be anxious 
and somewhat hypervigilant. When asked directly about his mental health he reports he has “psychotic reactions” from 
using cocaine and speed at times. When asked about his current drug use he states he is muscling about a gram of 
heroin a day and occasionally smoking crack. He reports using clonazepam when he can't get heroin or when he starts 
to feel "overamped."  
You refill his blood pressure medication (avoiding clonidine or beta blockers which could be problems considering his 
substance use.) You ask him if it would be okay to talk more about his drug use and possible treatment. He reports he 
was on methadone in the past and this kept him from using heroin. He stopped when he was incarcerated and had 
severe withdrawal because they did not give methadone or treat drug withdrawal in prison. He would like to stop 
heroin before his habit gets bigger and he lands back in prison or overdoses like a buddy of his recently did. He does 
not want to starts methadone again because he sees the old timers in the methadone clinic are usually "bent over, 
limping and broken down." 
You explain that it is true that many people on methadone maintenance have had a lifetime of injuries and often didn't 
get proper medical care that has resulted in their conditions. He easily relates to this. You also explain that there is no 
direct effect of methadone on bones and that it is a common myth that methadone eats up your bones. You explain that 
heroin and methadone have been associated with low testosterone and low vitamin D (explaining that vitamin D 
depends on plenty of exposure to the sun on exposed skin, which is something that many heroin users don't get). You 
tell him that you monitor testosterone and vitamin D levels for your patients on methadone to prevent these problems. 
He appears grateful for this information and states he knows the locations of the local methadone programs that accept 
Medi-Cal. He knows the location of the local syringe exchange and has gotten overdose prevention education and 
naloxone there. As the patient leaves you feel very uncertain whether you have helped him. You wonder if you should 
have raised the issue of buprenorphine but you know bupe prescribers in your community are very hesitant to 
prescribe to polysubstance users, especially if they use benzodiazepines.  
He returns to urgent care 3 months later with cold symptoms. He is profusely grateful to you for your advice and states 
he has been on methadone for about 3 months. His dose is now 110 mg which he feels holds him. He appears less 
anxious. He is considering entering a residential program for his other drug use. He is clear that when he has gotten 
clean in the past he always craved heroin first and then the other drugs followed. He thinks things might be different if 
he does a program and stays on methadone maintenance. He also reports he has told all his friends about the 
testosterone and vitamin D thing. He is amenable to seeing you in primary care because “you're cool.” 
 
Barry Zevin, MD, Tom Waddell Health Center,  
San Francisco Department of Public Health, San Francisco, California (2014) 
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Harm Reduction Practice Guidelines for Working with Homeless Opiate Users
by Patt Denning, PhD and Jeannie Little, LCSW
BACKGROUND AND HISTORY
In response to an increase in hepatitis B among people injecting drugs in Rotterdam, the 
Netherlands in the mid – 1980s, drug users organized themselves into “junkie unions” to petition 
the Health Department for injection equipment.  Syringe exchange as a public health intervention 
was born.
In mid – late 1980s in UK and Australia, partly in response to the emerging HIV epidemic, 
syringe exchange and drug programs, often funded by government, experimented with a range of 
services designed to attract users by responding to their real needs, which come to be collectively 
termed “Harm Reduction” services.  The model of Harm Reduction developed in Merseyside, 
UK included safe injecting education, drug substitution maintenance other than methadone, 
methadone maintenance options (by dose and mode of injection) and non-drug related 
interventions.
WHAT IS HARM REDUCTION?
Harm reduction is an approach to working with drug users that aims to reduce drug-related harm 
to individuals, their families, and communities without necessarily reducing the consumption of 
drugs and alcohol.  The damage done by drug and alcohol use, not necessarily the drug use itself, 
is the focus of attention.  Harm reduction doesn’t get caught up in arguments about whether 
people should or should not use drugs.
The term harm reduction was coined in the 1980’s to describe public health approaches to 
working with drug use.  At that time, the goal of harm reduction was to reduce the transmission 
of blood-borne diseases, specifically Hepatitis B and HIV.  It was based on the reality that all 
behavior change (leaving a relationship, changing sexual habits, changing diet, getting 
psychiatric treatment, deciding to take meds for HIV, deciding to reduce or quit drugs or 
alcohol…) requires a process of decision-making for successful implementation of a plan of 
change.  Ambivalence and resistance are normal and expected parts of the change process. It was 
far too important to save lives by offering immediate practical interventions than to get involved 
in whether or not people should or should not be using drugs.
Harm reduction includes a range of evidence-based approaches that recognize that people 
unable or unwilling to abstain from drug and harmful alcohol use can still make positive 
choices to protect their health, and the health of their families and communities. 
Currently in the United States, harm reduction is practiced in three broad arenas:
 Public health approaches include needle exchange, non-discriminatory healthcare, overdose 
prevention, and pill testing in clubs to reduce physical harm (e.g., HIV/HCV transmission) 
related to drug use.  Under the public health umbrella, harm reduction services include low-
threshold housing that does not discriminate against drug users and that provides adequate 
and relevant supportive services.  They also include interventions such as drug substitution 
therapies (e.g., methadone and buprenorphine).  The most recent innovation in public health 
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for drug users is the creation of safe injection facilities to ensure clean, safe drug use for 
people who do not have sanitary conditions for drug consumption.  While there are no 
facilities in the U.S., Canada has a safe injection facility and has embraced harm reduction as 
part of its public health philosophy, as have many countries around the world.
 Advocacy for the decriminalization of drug use, fair sentencing laws, medical marijuana to 
reduce harm done by the War on Drugs, and other sane drug policies.  The drug war is 
wholly responsible for the explosion of the U.S. prison population since the mid-1980’s.  The 
vast majority of people imprisoned for drug offences are people of color.  More harm has 
been done by the War on Drugs than by drug use itself. 
 Harm Reduction Therapy, a clinical approach to facilitate change in harmful drug using 
behaviors.  The approach is unique in that treatment is offered to active drug users and it is 
entirely client-centered.  The goals and the pace of treatment are determined by the client, not 
the therapist or counselor.
The principles of harm reduction are sufficiently broad that they have been applied to any low-
threshold, inclusive and non-discriminatory approach to working with other issues, from 
domestic violence to severe mental illness to chronic homelessness.
Bringing harm reduction principles to addiction treatment could mean that more individuals 
begin to engage in the harm reduction-addiction treatment continuum, further increasing the 
cost-efficiency and –effectiveness of public investments. 
Harm reduction is an empowerment model that turns control over to consumers who choose their 
own goals for and pace of change.  There is no requirement that substance users embrace 
abstinence or any other particular change goal.  This opens the doors to anyone who uses 
substances in a way that might be unsafe or problematic.  Many harm-reducing and change 
strategies belong under the harm reduction umbrella -- low threshold health interventions such as 
syringe access, overdose prevention, and supervised injection that bring active users who may 
have no interest in changing their drug use into a healthcare environment that meets their needs; 
harm reduction therapy that uses strategies such as motivational interviewing to motivate change 
and safer substance use education such as moderation or substance use management, all within a 
relational approach that respects client autonomy and choice.  These programs reach people who 
would not enter a traditional treatment program.  Strategies include 1) offering a full array of 
services needed by drug users to engage them in a service relationship, 2) creating a continuum 
of treatment options that offer substance users a full array of options for change and 3) 
integrating mental health and substance use treatment models and funding streams.
HARM REDUCTION PRINCIPLES
Not all drug use is abuse.
 Intoxication has been a normal part of human experience forever, a part of sacred or social  
ritual in every part of the world.  
 Most people in the U.S. use some type of drug, and most do not have problems. Moreover, 
most can and do make rational choices about, and while, using drugs.
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 Drug use occurs on a continuum from benign to chaotic, and people move back and forth 
between those poles throughout their drug-using lifespan, most never reaching the point of 
chaos.
 Drug abuse is a health, not a legal or moral concern – There should be no punitive sanctions 
for what a person chooses to, or refuses to, put into her/his body.
People use drugs for reasons.  
 New learning in neurobiology supports the fact that people, especially those with physical, 
mental or emotional illness, get significant relief from street drugs. 
 People don’t usually have the disease of addiction, they have a relationship with drugs.
 Harm is relative – depending on one’s reason for using, drugs may be preferable to one’s 
experience without them.
Incremental change is normal and motivation is fluid.
 The Stage Model of Change, based on research, explains the process that we go through to 
make major behavior change and asserts that change is most effective if we work through the 
stages one at a time, thoroughly, in order, and preferably with support.
Harm Reduction is a collaborative process model, not an outcome, model.
 Harm reduction requires that the drug user and the treatment provider work together to 
identify the problems and to plan solutions.  A combination of Drug, Set, Setting and the 
Stage Model of Change help to establish each drug user’s Hierarchy of Needs (treatment 
goals).
 Self-Determination Theory informs us that client-driven, not externally-driven, goals are 
most highly correlated with intrinsic motivation and therefore with successful change.
 Motivational Interviewing is the most useful model for facilitating motivation and change.
 Fundamental to harm reduction is to start where the client is and treat drug users with respect 
– people have the right to make their own choices, including “bad” ones.
Outcomes are as varied as the people seeking change; this is not only real, it is desirable!
 Abstinence is one of many harm reduction goals, it just isn’t the only one.
 At any point in time, most people in the United States with drug problems are not abstinent.  
 To date, treatment has abysmal abstinence outcomes, but much better harm reduction 
outcomes.
Harm reduction requires of practitioners ---
 A recognition that people will drink and use drugs, sometimes with harmful consequences to 
themselves and others
 Belief that what we call “addiction” is actually a complex phenomena encompassing 
biological, psychological, and social-cultural factors, rather than simply a brain disease.
 Commitment to working with people “As they are” and setting no goals or outcomes that are 
not freely chosen by the person. The continuum of drug use is mirrored in a continuum of 
care and goals.
 Affirmation that drug users should have an active voice in their treatment, and that they are 
the main agents of change
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HARM REDUCTION THERAPY
Harm reduction therapy developed first as a non-abstinence-based clinic and therapy office-
based method of treating people with drug and alcohol problems.
This section describes the application of the principles and practices of harm reduction therapy in 
community settings with complex, often opiate dependent people. Low-threshold welcoming and 
flexible session arrangements are defining characteristics of this community-based approach. 
Much effort goes into engaging people who have been shunned by mental health programs or 
have failed in substance abuse treatment programs.
Developed during the 1990’s by several practitioners (Springer,1991, Denning, 1998, Denning & 
Little 2012, Tatarsky, 1998 & 2002, Little, 2001 & 2002) and a researcher (Marlatt (2013), harm 
reduction therapy has grown over the last 18 years as an alternative approach to treating people 
with drug and alcohol problems.  Harm reduction therapy (HRT) is based on the understanding 
that drug and alcohol problems are multi-determined, and that each individual has a unique and 
idiosyncratic relationship with his or her drugs.  Any resulting treatment should be entirely 
individualized, with a different course and different outcomes for each person. Harm reduction 
and harm reduction therapy principles of respect, collaboration, incremental client-driven 
change, and offering a menu of options for behavior change all support an individualized 
approach and especially support an approach that encourages clients to make their own decisions 
about whether to come or not come to treatment.
A unifying principle of HRT is that drug users do not have to quit in order to reduce harm or to 
resolve their problems with drugs. While it recognizes and supports abstinence as a worthy goal 
of treatment, it is not by any means the only goal, and it is only a legitimate goal if proposed by 
the client.  The ultimate goal of harm reduction is not abstinence.  At the risk of stating a 
redundancy, the goal of harm reduction is harm reduction!  
We think of these individuals as exquisitely complex, as they present a multiplicity of priorities, 
both for themselves and for the therapists working with them.  Our attempts to refer clients to 
other mental health or substance abuse programs, and the clients’ previous attempts at treatment, 
have been largely unsuccessful. Many of these individuals are unable to meet the high threshold 
requirements of other clinics, such as sitting quietly in a clinic waiting room, having the attention 
span or comprehension skills to fill out intake paperwork, or possessing the trust to enter an 
office with a staff person with the door closed.  HRTC requires none of these things; HRTC 
expressly developed its community-based programs to enable people to receive mental health 
and substance abuse treatment without having to satisfy any program criteria.
Key elements of harm reduction practice
Low threshold
Locate treatment activities in places where people congregate for non-therapeutic reasons – street 
corners, community drop-in centers, needle exchanges, and primary care clinics.
A fundamental characteristic of community-based treatment is that the frame of the treatment is 
informed by the needs of the members of the community in which the program is located.  In a 
community whose members are dealing with survival needs, such as finding a place to sleep for 
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the night or getting something to eat, a program that required appointments in order to access its 
resources would not be an example of community-based treatment.  Such a program might fit in 
a community whose members have access to instrumental needs such as food, clothing, and 
shelter, but its high threshold would be a barrier in a community whose members struggle to 
meet those needs on a daily basis.  
Integrated
HR-informed treatment is integrated.  We pay equal attention to drug problems, mental illness, 
and other psychosocial problems.  It is the client’s hierarchy of needs that determines the focus 
of therapy on any given day.
HRP integrates several therapeutic approaches:  motivational interviewing (Miller & Rollnick, 
2003); cognitive-behavioral skills training (Moderation Management (Kern,et al,20…)stress 
reduction, mindfulness, substance use management (Bigg, 2001), life coaching (money 
management, nutrition, other life skills); and nonverbal approaches such as drumming (Schultz, 
2006) and somatic experiencing (Levine, 1997).  All of these approaches and interventions take 
place in a context of relational psychodynamic therapy (Rothschild, 2007) and of modern 
analytic processes of emotional communication and joining (relational alternatives to analytic 
interpretation) (Ormont, 1992). 
Trauma Informed
Program structures and therapist expectations must avoid replicating any of the key 
characteristics of trauma. Important elements of trauma include coercion, intrusion, loss of 
control, powerlessness, loss of trust, often an element of surprise, and physical and emotional 
attacks.  Trauma survivors have great difficulty developing trust.  They are hypervigilant.  They 
doubt the safety of their surroundings.  Enormous numbers of trauma survivors abuse alcohol 
and drugs (Goetz, 2003; Little, 2012).  Programs must first of all do nothing that replicates the 
characteristics of traumatic experiences.  They must then 
Takes into account the impact of past experiences on the present
Each client has both a real and a transferential relationship with his or her therapist, with host 
agencies, and with the context in which our programs are held.  The real relationship is based on 
the actual encounters each client has with staff and structures.  How accommodating is the 
schedule?  How accessible are the rooms?  Are they decorated with comfort and warmth in 
mind?  Does staff greet prospective clients with a big smile and a warm welcome or with a rote 
“What do you need today?”  Is staff interested and curious or anxious to get on with the business 
of the encounter?  These factors, and many more, trigger responses in each client and influence 
the subsequent course of the work.
Each client also approaches the agency and its staff with expectations.  These expectations are 
formed by prior experiences of treatment at the hands of other institutions, social service 
agencies, and treatment programs.  Given the clients’ multiple problems, and given that most 
have been in the foster care and/or criminal justice system, these experiences have been largely 
negative.  The job of the harm reduction therapist (and others) is to undo negative expectations 
by repeatedly expressing welcoming affect, making affirming statements, and offering a 
respectful and collaborative relationship.  
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SPECIFIC PRACTICE GUIDELINES
Set the stage for honest communication: Relationship
Above all, we view everything that we do as treatment, from the briefest hello to an ongoing 
therapy relationship. We view all interactions as in the service of building and maintaining the 
therapeutic relationship, knowing that relationship is the key to all behavior change. We build 
relationships by providing the space and time for people to either move toward us, or to invite us 
to move toward them in their time, not ours.
No punitive sanctions for drug use
Policies regarding opiate or other drug use during treatment must be as permissive as possible 
given safety (overdose) concerns. Refusing or significantly restricting services in response to 
illicit drug or alcohol use will only increase the chances that clients will lie to us and engage in 
other behaviors that we interpret as “drug seeking”. More frequent contact, honest exchange of 
conflicts, and adjusted dosing schedules should be the primary interventions.
Flexible and non-contingent dosing schedules/locations, etc.
Flexibility is the key to beginning a therapy relationship. Services should offer drop-in or 
sidewalk sessions, drop-in support groups, regular therapy appointments, and psychiatric 
medications This means meeting and engaging individuals on the street, in the waiting room, or 
outside a bathroom door to begin the process of developing a trusting relationship in which 
people can, over time, bring themselves to the therapeutic encounter and begin to see that 
relationship as a resource rather than an intrusion.  
Chronic stress must also be treated
Self medication is usually an important component of chronic opiate dependence. Lifestyles, 
homelessness, psychiatric issues, etc. are well soothed by opiates. Programs should provide 
clients opportunities for respite, relaxation, and fun.
Use adjunct medications to treat underlying depression and anxiety
When people move from personal opiate use to medically supervised use, they often find that the 
medicine doesn’t work as well for anxiety and depression. This can be a major source of relapse 
or of misusing prescribed medicines.
Assess stage of change for all target behaviors, symptoms, etc.
People may be ready to take action, adhere to different tx recommendations at different times. 
Welcomes people in crisis who present difficult behaviors : Work with difficult behaviors 
rather than prohibit them
We practice radical inclusion of all people, and all behaviors that they bring into our programs.  
We understand that behavior serves a purpose, and despite sometimes self-destructive aspects, it 
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communicates essential information about a person’s history, feelings, and response to the 
present environment.
Under the guise of creating “safety” for both clients and staff, programs frequently create rules 
and systems to prohibit these and many other “disruptive” behaviors.  Often this is more about 
staff comfort than actual safety.
At some point, most of our clients have crises.  All staff are trained in crisis evaluation and are 
authorized to commit clients to an involuntary hold if absolutely necessary, which it is not often.  
Crisis prevention is our priority; however, because emergency hospitalization is rarely 
therapeutic and is often traumatizing, we might spend hours talking with and settling a client 
who is in crisis in order to avert a dangerous situation.
Take care of staff
We also consider the care of our therapists a critical component of all programs. Opportunities 
for individual and group supervision must be standardized, and other stress-reducing components 
added (continuing education, vacations, communal lunches, etc.) Therapists must embody 
flexibility and responsiveness to 100 different crises and stories in any given day.  Just as the 
harm reduction therapist prioritizes developing the therapeutic relationship, the same is true for 
supervisors supporting harm reduction therapists as they offer their full attention to the many 
participants in our community-based programs.
8/29/2013
1/20/13 
 Name:                                                                         
Worksheet for DSM-V-TR criteria for Diagnosis of Opioid Use Disorders (DRAFT) 
Diagnostic Criteria 
(Use Disorder requires meeting 2 or more 
criteria; increasing severity of use disorder 
with increasing number of criteria met) 
Meets 
criteria 
Yes         No Notes/supporting information 
Recurrent substance use resulting in a 
failure to fulfill major role obligations at 
work, school, or home 
   
Recurrent substance use in situations in 
which it is physically hazardous 
   
Continued substance use despite having 
persistent or recurrent social or 
interpersonal problems caused or 
exacerbated by the effects of the 
substance 
   
 Tolerance, as defined by either of the 
following: 
   
(a) a need for markedly increased 
amounts of the substance to achieve 
intoxication of desired effect 
   
(b) markedly diminished effect with 
continued use of the same amount of 
the substance 
   
Withdrawal, as manifested by either of the 
following: 
   
(a) the characteristic withdrawal 
syndrome 
   
(b) the same (or a closely related) 
substance is taken to relieve or avoid 
withdrawal symptoms 
   
The substance is often taken in larger 
amounts or over a longer period of time 
than intended 
   
There is a persistent desire or unsuccessful 
efforts to cut down or control substance 
use 
   
A great deal of time is spent in activities 
necessary to obtain the substance, use 
of the substance or recover from its 
effects 
   
 Important social, occupational, or 
recreational activities are given up or 
reduced because of substance use 
   
1/20/13 
 Name:                                                                         
Worksheet for DSM-V-TR criteria for Diagnosis of Opioid Use Disorders (DRAFT) 
Diagnostic Criteria 
(Use Disorder requires meeting 2 or more 
criteria; increasing severity of use disorder 
with increasing number of criteria met) 
Meets 
criteria 
Yes         No Notes/supporting information 
The substance use is continued despite 
knowledge of having a persistent or 
recurrent physical or psychological 
problem that is likely to have been 
caused or exacerbated by the substance 
   
 
Craving or a strong desire to use opioids    
 
Number of Diagnostic Criteria Met:________ 
 
Diagnosis/Severity: __________ 
Moderate: 2-3 criteria 






Signature  Date 
 
 





Established in 2009, Albuquerque Health Care for the Homeless’ (AHCH) Re-Entry Collaborative (REC) is 
designed to reduce human suffering in Bernalillo County residents who are opiate addicted, without homes, and 
recently released from incarceration, and to reduce the societal damage and systems costs that result from crime and 
rearrest/conviction that occur in the event of a relapse, including reduced overdose deaths.  Community partners 
include: the NM Department of Health; Bernalillo County Substance Abuse Treatment Services; the NM 





Integrated primary care and social services treatment model, including a) opiate replacement therapy using 
Suboxone, b) enhanced services through Care Coordination, c) Stages of Change and Motivational Interviewing for 
individual risk reduction, including overdose prevention training and Narcan distribution, d) Housing First 
philosophy for ending homelessness, e) substance abuse treatment group, f) Trauma Informed Care, and g) 
















Notes from the Director 
 
The Re-Entry Collaborative is a reflection of AHCH’s commitment to 
tangible collaboration across sectors, and to very innovative but practical 
solutions for people struggling with substance use disorders in our 
community.  We appreciate our partners’ willingness to share leadership 
in making this happen.  Together we have proven that a smart mix of 
community-based care, access to medications, like Suboxone and Narcan, 
matched with wrap-around social services and behavioral health do end 
homelessness, end untimely opiate overdoses and keep people from re-
entering the criminal justice system.  See below for more on the facts.  
 
 
Since February 2009, REC has 
enrolled 405 clients.  Key outcomes 
include:   
 
• Increased the rate of abstinence 
79%. 
 
• Increased the number of clients 
with stable housing 517%. 
 
• A 37% increase in employment or 
attending school. 
 
Your continued support makes it possible. We 
appreciate our clients, their families and friends, 
and our community partners. 
 
 




Drug Use at Intake for the last 30 days  
The top six drugs clients reported using at Intake are 
described in the following table.  
 
Top Six Drugs Clients Reported Using at Intake 
Rank Drugs Used Percent 
Reported 
1 Heroin 56.2% 
2 Any Alcohol 37.7% 
3 Marijuana/Hashish 26.5% 
4 Cocaine/Crack 21.6% 
5 Oxycontin/Oxycodone  8.0% 
6 Percocet  7.4% 
 
Drug use is not the only problem. 
• Almost 60% of people enrolled into REC 
reported serious depression not related to 
their drug use. 
 
• Almost 74% of people enrolled into REC 
reported serious anxiety not related to their 
drug use. 
 
• Over 84% of clients reported violence or 
trauma at intake into the program. 
 
The REC program decreases drug use; associated 
risky, unhealthy behaviors; and mood disorders. 
 
• Percent days of heroin use decreased from 
48.8% at intake, to 24.3% at 6 months post 
intake and decreased yet again to 18.5% at 
12 months post intake. 
 
• Injection drug use fell by over 50% from 
intake into the REC to 6 months post intake. 
 
• Clients reported fewer days of depression 
and anxiety after being in the REC. 
 
• Since January 2011 AHCH’s Harm Reduction 
Program has educated 237 people in the use 
of Narcan, a medication that reverses the 
effects of opiate overdose and saves lives. 
 
 
National Outcome Measures 
 
SAMHSA developed a set of National Outcome 
Measures that can be used to evaluate the 
effectiveness of programs.  AHCH’s REC program 
consistently improved the outcomes of our clients 
from intake to the 6-month follow-up.   
 
Change in National Outcome Measures From 










Abstinence:  No use of 
alcohol or illegal drugs 28.8% 51.7% 
Crime and Criminal Justice:  
had no past 30 day arrests 85.0% 88.3% 
Employment/ Education:  
were currently employed or 
attending school 19.1% 26.2% 
#Health/Behavioral/Social 
Consequences:  experienced 
no alcohol or illegal drug 
related health, behavioral, 
social consequences 61.8% 71.9% 
Social Connectedness:  were 
involved in the recovery 
community. 95.1% 92.5% 
Stability in Housing:  had a 
permanent place to live in 
the community 2.2% 13.9% 
 
Criminal Justice Involvement  
 
• Arrests decreased (3%) over the first 6 
months of the REC, but further decreased by 
about 11% at 12 months into the program.   
 
• This suggests longer program involvement and 
aftercare resources are necessary to have a 
larger effect on criminal justice involvement. 
PROJECT WORKPLAN through end of March 2013 
 
Goal 1: Improve the ability of ex-inmates to access and remain engaged in treatment services.   
 6-month f/u 
Objective 1: Among individuals who return for at least one visit after beginning to take 
buprenorphine, 80% will meet with a case manager or client advocate within one week of the first 
follow-up visit.  
403/435 (92.6%) 
 
Objective 2: Among individuals in maintenance treatment 75% will attend 2 or more support 
groups or individual counseling sessions on average during months 2-6.   
203/240 (84.6%) 
 
Objective 3: Among individuals in maintenance treatment 90% will meet with a case manager or 
client advocate at least 6 times during the first 6 months of treatment.   
198/240 (82.5%) 
 
Objective 4: 90% of individuals in maintenance treatment will have 2 or more clinic visits in the 
first 6 months in an integrated treatment setting that addresses addiction, physical, and mental 
needs e.g., AHCH or First Choice/First Nations.   
227/240 (94.6%) 
 
Goal 2: Achieve sustained recovery from opiate addiction following release from incarceration.   
 6-month f/u 
Objective 1: 60% of individuals in maintenance treatment report at the 6 month visit that they are 
still taking buprenorphine. 
178/240 (74.2%) 
 
Objective 3: Among individuals who meet the criteria for #1, above, 80% will test negative for 
opiates on the first urine tox screen obtained after completing 180 days of treatment. 
142/178 (79.8%) 
 
Goal 3: Improve housing status of participants.   
 Intake 6-month f/u 12- month f/u 
Objective 1: 50% of individuals in maintenance 
treatment will improve their housing status 
within the first 6 months.  
N/A 97/240 (40.4%) 
improved housing status at 6 
months  
N/A   
Objective 2: Of those who are housed or obtain 
housing during the grant period (i.e., have 
housing that is transitional, permanent 
supportive housing or permanent housing), 80% 
will remain housed at 12 months.   
N/A  N/A  75/82 (91.5%) 
Housed in transitional, 
permanent supportive 
or permanent housing. 
Goal 4: Decreased Recidivism. 
 12- month f/u 
Objective: For participants who complete 12 months of maintenance treatment, number of 
arrests for new charges during these 12 months will be decreased by at least 25% compared 
with the one year prior to their most recent incarceration.   
104/137 (75.9%) 
Completers that had zero new 
arrests or a decrease of 25% in 
new arrests. 
Goal 5: Improve quality of life for those engaged in maintenance treatment for at least 6 months.   
 6-month f/u 12- month f/u 
Objective 1: 60% will show 
reduced scores on Hopkins 
Symptom checklist.   
139/220 valid cases (63.2%) 
 
 
69/110 (62.7%)  
showed reduced scores for completers who 
were in maintenance treatment at 6 months 
 
Objective 2: 60% will 
demonstrate improvement in 
quality of life as measured by 
the Happiness Scale.  
Improved: 89/221 (40.3%)  
No Change:59/221 (26.7%)   See Note 1. 
Decline:  73/221 (33.0%)  
 
Improved: 49/116 (42.2%)   
No Change:35/116 (30.2%)  See Note 2. 
Decline: 32/116 (27.6%)  
 
Notes:  
Maintenance treatment is defined as receiving social services at 6 month point.  The denominator for the percentages varies 
according to the goal; the goals are progress measures and the denominators generally decrease towards the 12 month goals. 
1) 29 of the 59 clients that experienced no change reported “completely happy” at BOTH intake and 6 months.   
2) 19 of the 35 clients that experienced no change reported “completely happy” at BOTH intake and 12 months.  
COCAINE 
Cocaine may interact 
pharmacokinetically and increase drug 










Cocaine may react 
pharmacodynamically with the following 
formulary medications:
 Tricyclic Antidepressants-adrenergic 
stimulation
 BetaBlockers- unopposed alpha 
adrenergic stimulation (WHAT IS THE 
SIGNIFICANCE IN NON-OVERDOSE SITUATIONS?)
 SSRI-seretonin syndrome




 Clonidine-has been reported to 
increase CNS effects of cocaine.
The formation of the more toxic 





Heroin levels may be increased 
pharmacokinetically by the following 2 
pathways:
3A4 system promotes conversion to 




2D6 system promotes the metabolism and 
breakdown of morphine.  These formulary 
meds inhibit this system:
 bupropion (more likely)
 fluoxetine (more likely)
 paroxetine (more likely)
 duloxetine (less likely)
Heroin may react pharmacodynamically
with the following:
 Antihistamines- increase CNS 
effects (especially first generation 
antihistamines)
 Clonidine- Increase CNS effects, 
opioid sparing effects
METHAMPHETAMINE
Methamphetamine may react 




• Tricyclic Antidepressants-adrenergic 
stimulation
• Albuterol-adrenergic stimulation
• Beta Blockers- unopposed alpha 
adrenergic stimulation (IWHAT IS THE 
SIGNIFICANCE IN NON-OVERDOSE SITUATIONS?)
• Phenylephrine-adrenergic stimulation.
DEXTROMETHORPHAN
Dextromethorphan effects may be 
enhanced pharmacokinetically by the 
following:
 buproprion (more likely)
 fluoxetine (more likely)
 paroxetine  (more likely)
 duloxetine (less likely)
Dextromethorphan may react 
pharmacodynamically with the 
following:
 SSRI-seretonin syndrome
Pharmacokinetic Interaction- An interaction that occurs due to drug metabolism. 
More information on interaction affecting the cytochrome P450 pathway can be found at: 
http://medicine.iupui.edu/clinpharm/ddis/clinicalTable.aspx
Pharmacodynamic Interaction- An interaction that occurs through mechanisms of action.
Potential Interactions with Common Drugs of Abuse 
